

CURRICULUM VITAE
MARSHALL E. KADIN, M.D.

10/20/2021

Pathology and Laboratory Medicine
Rhode Island Hospital
Aldrich 301G
593 Eddy Street
Providence, RI 02903
Marshall_Kadin@Brown.edu

Department of Medicine, Dermatology Division
Roger Williams Medical Center
50 Maude Street
Providence, RI 02908

ORCID 0000-0003-1039-4384

EDUCATION

Undergraduate Northwestern University, Evanston IL, BA 1961
Medical School Northwestern University, Chicago IL, MD 1965

POSTGRADUATE TRAINING

Internship Milwaukee Country General Hospital, Milwaukee, WI, Medicine and
Surgery 1965-1966
Residency Washington University-Barnes Hospital, St. Louis, MO, Pathology 1966-
1968
Fellowship-NIH, Stanford University, Palo Alto, CA, Surgical Pathology 1968-1970
Fellowship- University of California, San Francisco, CA, Clinical Hematology 1972-1973

HONORS

1961 Phi Beta Kappa, Northwestern University
1993 President- American Association for Cancer Research, Boston Chapter
1972 1992-present Elected to Best Doctors in America
1997 Stowell-Orbison Award for sponsorship of outstanding resident paper,
US/Canadian Academy of Pathology
2002 Certificate of Appreciation to an Extraordinary Colleague, Mentor, Teacher
and Friend from the Hematologic Malignancy, Hematopathology and Bone
Marrow Transplant Team, Beth Israel Deaconess Medical Center and
Harvard Medical School
2017 Member, Royal Society of Medicine

MILITARY SERVICE

07/16/1970 – 07/13/1972
Major, U.S. Army Medical Corps

Bronze Star Medal, National Defense Service Medal, Vietnam Campaign Medal, Vietnam Service Medal, United States Army Medical Corps

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Licensure

1965 State of Wisconsin, No. 15964 – inactive
1965 State of California, No. G13173 – inactive
1977 State of Washington, No. 252-090016165 – inactive
1984 State of Massachusetts, No. 53780 – inactive
2007 State of Florida, No. ME 99787, Control No. 516940 – inactive
2002 State of Rhode Island, MD11034 expires 6.30.23
DEA registration number BK4933304, expires 12.31.2022

Certification

1972 American Board of Pathology, Anatomic Pathology
1978 American Board of Pathology, Hematology (Special Competence)
1988 Certification for the safe use of radioisotopes in research

ACADEMIC APPOINTMENTS

1973-1977 Assistant Professor of Medicine and Clinical Pathology, University of California, San Francisco, CA
1977-1982 Associate Professor of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
1980-1982 Associate Member, Fred Hutchinson Cancer Research Center, Seattle WA
1981-1982 Adjunct Associate Professor of Medicine, University of Washington
1982-1984 Professor of Laboratory Medicine and Pathology, Adjunct Professor of Medicine, University of Washington
1982-1984 Full Member, Fred Hutchinson Cancer Research Center
1984 Visiting Professor, Department of Pathology, University of Kiel, Germany
1984-2002 Associate Professor of Pathology, Harvard Medical School
1998-2007 Full Member, Dana-Farber Cancer Center, Boston, MA
2000-2001 Visiting Professor, Institute of Dermatology, University of Zurich
2002-2004 Associate Clinical Professor of Pathology, Harvard Medical School
2009-present Professor of Dermatology, Boston University, Boston, MA
2019-present Professor of Pathology and Laboratory Medicine (research) Brown University Alpert Medical School, Providence RI

HOSPITAL APPOINTMENTS

1972-1977 Consultant in Hematology, University of California, San Francisco
1977-1984 Director of Hematology Laboratory and Hematopathology, University of Washington Hospital, Seattle, WA
1984-2002 Director of Hematopathology, Beth Israel Hospital, Boston, MA
1984-2004 Senior Pathologist, Beth Israel Hospital, Boston, MA
1990-1996 Consultant in Pathology, New England Deaconess Hospital
1991-1995 Attending Physician, Autopsy service, Beth Israel Hospital
1992-2005 Consultant in Dermatopathology, Harvard Medical School

MARSHALL E. KADIN, M.D.

1992-2002 Director Hematopathology Fellowship Program, Beth Israel Hospital
1998-2005 Associate Director, Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, MA
1998-2005 Member, Beth Israel Deaconess Medical Cancer Center
1998-2005 Member, Harvard-Dana Farber Cancer Center
2002-2005 Consultant in Pathology, Beth Israel Deaconess Medical Center, Boston, MA
2005-2009 Skin Disease Research Center, Harvard Institutes of Medicine
2007-present Chief, Immunopathology and attending physician in Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Providence, RI
2016-2019 Research Scientist, Department of Pathology, Rhode Island Hospital
2016-2019 Consultant in Pathology, Department of Pathology, Rhode Island Hospital

OTHER APPOINTMENTS

Major Administrative Responsibilities

1977-1984 Director of Hematopathology, University of Washington, Seattle, WA
1978-1984 Co-Director, Laboratory Medicine Residency Training Program, University of Washington
1984-2000 Director of Hematopathology and Bone Marrow Service, Beth Israel Deaconess Medical Center (BIDMC)
1984-2002 Co-director, Immunopathology Laboratory, BIDMC
1990-2002 Chairman, Bone Marrow Quality Assurance Committee, BIDMC
1992-2002 Director ACGME Accredited Hematopathology Fellowship Training Program, BIDMC
1998-2004 Associate Director, Cutaneous Oncology Program, BIDMC
2008-2013 Director, Imaging Core Facility, Roger Williams Medical Center
Associate Director, Image Bank, American Society of Hematology

HOSPITAL COMMITTEES

1977-1981 Immunology Committee, Children's Cancer Study Group
1980-1984 Pathology Committee, Southwest Oncology Group
1981-1984 Pathology Committee, Children's Cancer Study Group
1982-1984 Hodgkin's Disease Strategy Committee, Children's Cancer Study Group
1984-1987 Executive Committee
1990-2000 Director, Hematopathology Fellowship Training Program, Beth Israel Deaconess Medical Center
1990-2000 Director Bone Marrow Interpretation Quality Control Committee
2000 Chair, Search Committee, Director of Hematology Laboratory, Beth Israel Deaconess Medical Center
2008-2014 Cancer Committee, Roger Williams Medical Center
2013 Search Committee, Chair Department of Dermatology, Roger Williams Medical Center
2017 Nominating Committee for Officers of Medical Staff, Roger Williams Medical Center

MARSHALL E. KADIN, M.D.

1984-1987	Chairman, Committee for Immunohistochemistry of Hodgkin's Disease, Children's Cancer Study Group
1984-1990	Non-Hodgkin's Lymphoma Strategy Committee, Children's Cancer Study Group
1984-1990	Primary Review Pathologist for Children's Cancer Study Group Lymphoma Protocols 501, 502, 503, 552, 5911 & 5006
1984-1990	Reference Immunopathologist for Hodgkin's Disease and Non-Hodgkin's Lymphomas, Children's Cancer Study Group
1997-2000	Associate Director, Lymphoma Biology Reference Laboratory, Children's Cancer Study Group
1997-1999	External Advisory Committee, Chemoprevention and Genetically-Identified High-Risk Groups: Interactive Research and Development Projects, Children's Cancer Study Group.
1997-2000	Eastern Cooperative Oncology Group- Leukemia Studies Core Committee
1997-2000	Co-Director, Lymphoma Biology Resource Laboratory, Children's Cancer Study Group
1998-2000	Co-Chairman, Lymphoma Strategy Committee of The Children's Cancer Study Group
1998-2000	Member, Committee on Biology and Translational Research, Children's Cancer Study Group
1998-2000	Member, Steering Committee, Hodgkin's Disease, Children's Oncology Group

UNIVERSITY COMMITTEES

1977-1984	Cancer Institutional Grant Review Committee, University of Washington
1978-1984	Co-Director, Residency Committee, Laboratory Medicine, University of Washington
1994-1996	Harvard Collaborative Oncology Group Lymphoma Committee

MEMBERSHIPS IN SOCIETIES

1972-present	American Society of Hematology
1972-Present	International Academy of Pathology
1974-Present	American Association for Cancer Research
1977	Academy of Clinical Laboratory Physicians and Scientists
1977-1982	American Society of Cytology
1984-Present	Society for Hematopathology
1984-1988	Member, NIH Pathology Panel for Lymphoma Clinical Studies
1986-1989	Chairman, Publications Committee, Society for Hematopathology
1988-1990	Chairman Nominating Committee, Society for Hematopathology
1990-1992	American Society of Clinical Pathologists
1993-1994	President, Boston Chapter, American Association for Cancer Research
1994-1996	Member Scientific Subcommittees on Immunohematology and Lymphocyte Biology, American Society of Hematology
1994-2006	European Association for Hematopathology
1994-Present	Society of Investigative Dermatology
1996-Present	International Society for Cutaneous Lymphomas
1996- Present	United States Consortium for Cutaneous Lymphomas

2021- Present American Society of Investigative Pathology

EDITORIAL BOARDS

1984-present American Journal of Surgical Pathology
1984-2005 Human Pathology
1985-1992 Cancer
1994-2002 International Journal of Hematology
1998-2003 Blood
2000-2008 American Journal of Dermatopathology
2002-2007 Associate Editor, American Society of Hematology Image Bank

MAJOR COMMITTEE ASSIGNMENTS

Federal Government
1984-1988 Member, NIH Pathology Panel for Lymphoma Clinical Studies, Henry Rappaport, MD Chairman
1996 NIH Study section reviewer in Pathology

Advisory Boards Leo Pharma- 2016-19
 Allergan, Inc- 2016-19
 Malinckrodt- 2016
 Seattle Genetics- 2018

PUBLICATION LIST

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Oftedal G, Prenskey AL, **Kadin M**, Nelson J. Amyotrophic lateral sclerosis in childhood. Trans Am Neurol Assoc. 1969;94:96-9. Epub 1969/01/01. PubMed PMID: 5374495.
2. Sapse AT, Bonavida B, **Kadin M**, Stone W, Jr., Sercarz EE. Smog eye irritation: effect of air pollution on the tear protein pattern. Ophthalmologica. 1969;158 Suppl:421-7. Epub 1969/01/01. PubMed PMID: 4188140.
3. **Kadin ME**, Donaldson SS, Dorfman RF. Isolated granulomas in Hodgkin's disease. N Engl J Med. 1970;283(16):859-61. Epub 1970/10/15. doi: 10.1056/NEJM197010152831609. PubMed PMID: 5458036.
4. **Kadin ME**, Rubinstein LJ, Nelson JS. Neonatal cerebellar medulloblastoma originating from the fetal external granular layer. J Neuropathol Exp Neurol. 1970;29(4):583-600. Epub 1970/10/01. PubMed PMID: 5471923.
5. **Kadin ME**, Bensch KG. Comparison of pheochromocytes with ganglion cells and neuroblasts grown in vitro. An electron microscopic and histochemical study. Cancer. 1971;27(5):1148-60. Epub 1971/05/01. PubMed PMID: 4103340.
6. **Kadin ME**, Bensch KG. On the origin of Ewing's tumor. Cancer. 1971;27(2):257-73. Epub 1971/02/01. PubMed PMID: 5100390.
7. **Kadin ME**, Glatstein E, Dorfman RF. Clinicopathologic studies of 117 untreated patients subjected to laparotomy for the staging of Hodgkin's disease. Cancer. 1971;27(6):1277-94. Epub 1971/06/01. PubMed PMID: 5088206.

8. Silverberg GD, **Kadin ME**, Dorfman RF, Hanbery JW, Prolo DJ. Invasion of the brain by a cellular blue nevus of the scalp. A case report with light and electron microscopic studies. *Cancer*. 1971;27(2):349-55. Epub 1971/02/01. PubMed PMID: 5100398
9. Jones SE, Rosenberg SA, Kaplan HS, **Kadin ME**, Dorfman RF. Non-Hodgkin's lymphomas. II. Single agent chemotherapy. *Cancer*. 1972;30(1):31-8. Epub 1972/07/01. PubMed PMID: 4557278.
10. Sukoff MH, **Kadin MM**, Moran T. Transoral decompression for myelopathy caused by rheumatoid arthritis of the cervical spine. Case report. *J Neurosurg*. 1972;37(4):493-7. Epub 1972/10/01. doi: 10.3171/jns.1972.37.4.0493. PubMed PMID: 5070876.
11. England JM, **Kadin ME**, Goldstein MN. The effect of vincristine sulphate on the axoplasmic flow of proteins in cultured sympathetic neurons. *J Cell Sci*. 1973;12(2):549-65. Epub 1973/03/01. PubMed PMID: 4122254.
12. Jones SE, Fuks Z, Bull M, **Kadin ME**, Dorfman RF, Kaplan HS, Rosenberg SA, Kim H. Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. *Cancer*. 1973;31(4):806-23. Epub 1973/04/01. PubMed PMID: 4574662.
13. **Kadin ME**. Invited discussion: In vitro study of multinucleated cells in Hodgkin's disease. *Natl Cancer Inst Monogr*. 1973;36:211-7. Epub 1973/05/01. PubMed PMID: 4744581.
14. **Kadin ME**, Asbury AK. Long term cultures of Hodgkin's tissue. A morphologic and radioautographic study. *Lab Invest*. 1973;28(2):181-4. Epub 1973/02/01. PubMed PMID: 4687527.
15. **Kadin ME**, Newcom SR, Gold SB, Stites DP. Letter: Origin of Hodgkin's cell. *Lancet*. 1974;2(7873):167-8. Epub 1974/07/20. PubMed PMID: 4135566.
16. **Kadin ME**, Thompson RW. Lymphangiography. Its practical value in surgically staged patients with Hodgkin's disease. *West J Med*. 1974;120(3):193-9. Epub 1974/03/01. PubMed PMID: 4816398; PMCID: PMC1129383.
17. Kay MM, **Kadin M**. Letter: Surface characteristics of Hodgkin's cells. *Lancet*. 1975;1(7909):748-9. Epub 1975/03/29. PubMed PMID: 47512.
18. **Kadin ME**, Gold S, Garratty EM, Stites DP. Immunological membrane markers of Hodgkin's cells. *Hamatol Bluttransfus*. 1976;19:229-36. Epub 1976/01/01. PubMed PMID: 1087621.
19. Barrett SG, Schwade JG, Ranken R, **Kadin ME**. Lymphoblasts with both T and B markers in childhood leukemia and lymphoma. *Blood*. 1977;50(1):71-9. Epub 1977/07/01. PubMed PMID: 326316.
20. **Kadin M**, Billing RJ. Immunofluorescent method for positive identification of null-cell type acute lymphocytic leukemias: use of heterologous antiserum. *Blood*. 1977;50(5):771-82. Epub 1977/11/01. PubMed PMID: 332257.
21. Perkins HA, McIlroy M, Swanson J, **Kadin M**. Transient LW-negative red blood cells and anti-LW in a patient with Hodgkin's disease. *Vox Sang*. 1977;33(5):299-303. Epub 1977/01/01. PubMed PMID: 411256.
22. **Kadin ME**, Billing RJ. B lymphocyte antigens in the differential diagnosis of human neoplasia. *Blood*. 1978;51(5):813-23. Epub 1978/05/01. PubMed PMID: 346089.
23. **Kadin ME**, Stites DP, Levy R, Warnke R. Exogenous immunoglobulin and the macrophage origin of Reed-Sternberg cells in Hodgkin's disease. *N Engl J Med*. 1978;299(22):1208-14. Epub 1978/11/30. doi: 10.1056/NEJM197811302992203. PubMed PMID: 101841.
24. Newcom S, **Kadin ME**. T-cell leukemia with involuted thymus in a patient receiving Dilantin therapy. *Cancer* 1979; 43:622-626.
25. Newcom SR, **Kadin ME**. Prednisone in treatment of allergen-associated angio-immunoblastic lymphadenopathy. *Lancet*. 1979;1(8114):462-4. Epub 1979/03/03. PubMed PMID: 85054.

26. Newcom SR, **Kadin ME**. T-cell leukemia with thymic involution. *Cancer*. 1979;43(2):622-6. Epub 1979/02/01. PubMed PMID: 311242.
27. Newcom SR, Resser KJ, **Kadin ME**. Immunoblastic lymphoma in angio-immunoblastic lymphadenopathy. *Lancet*. 1979;2(8139):420. Epub 1979/08/25. PubMed PMID: 89475.
28. Sybert VP, Setran KN, **Kadin ME**. Lymphocyte capping in carriers of Duchenne muscular dystrophy. *N Engl J Med*. 1979;301(13):724-5. Epub 1979/09/27. PubMed PMID: 481471.
29. Bowles CA, Bull M, McCormick K, **Kadin M**, Lucas D. Autologous bone marrow transplantation following chemotherapy and irradiation in dogs with spontaneous lymphomas. *J Natl Cancer Inst*. 1980;65(3):615-20. Epub 1980/09/01. PubMed PMID: 6997586.
30. **Kadin ME**. Ia-like (HLA-DR) antigens in the diagnosis of lymphoma and undifferentiated tumors. *Arch Pathol Lab Med*. 1980;104(10):503-8. Epub 1980/10/01. PubMed PMID: 6998408.
31. **Kadin ME**. A reappraisal of the Reed-Sternberg cell: a commentary. *Blood Cells*. 1980;6(3):525-32. Epub 1980/01/01. PubMed PMID: 6994843.
32. **Kadin ME**. T gamma cells: a missing link between malignant histiocytosis and T cell leukemia-lymphoma? *Hum Pathol*. 1981;12(9):771-2. Epub 1981/09/01. PubMed PMID: 6975747.
33. **Kadin ME**, Kamoun M, Lamberg J. Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. *N Engl J Med*. 1981;304(11):648-53. Epub 1981/03/12. doi: 10.1056/NEJM198103123041106. PubMed PMID: 6969851.
34. **Kadin MR**. Staging laparotomy in Hodgkin's disease. *Arch Surg*. 1981;116(3):367-8. Epub 1981/03/01. PubMed PMID: 7469784.
35. Kamoun M, **Kadin ME**, Martin PJ, Nettleton J, Hansen JA. A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. *J Immunol*. 1981;127(3):987-91. Epub 1981/09/01. PubMed PMID: 6790625.
36. Peterson AP, Altman LC, Hill JS, Gosney K, **Kadin ME**. Glucocorticoid receptors in normal human eosinophils: comparison with neutrophils. *J Allergy Clin Immunol*. 1981;68(3):212-7. Epub 1981/09/01. PubMed PMID: 7264103.
37. Poore TE, Barrett SG, **Kadin ME**, Bainton DF. Ultrastructural localization of acid phosphatase in rosetted T and B lymphocytes of normal human blood. *Am J Pathol*. 1981;102(1):72-83. Epub 1981/01/01. PubMed PMID: 6970526; PMCID: PMC1903428.
38. **Kadin ME**. Possible origin of the Reed-Sternberg cell from an interdigitating reticulum cell. *Cancer Treat Rep*. 1982;66(4):601-8. Epub 1982/04/01. PubMed PMID: 6951633.
39. **Kadin ME**, Kamoun M. Nonendemic adult T-cell leukemia/lymphoma. *Hum Pathol*. 1982;13(8):691-3. Epub 1982/08/01. PubMed PMID: 6980817.
40. **Kadin ME**, Kamoun M. Adult T cell lymphoma-leukaemia in U.S. whites. *Lancet*. 1982;1(8279):1016-7. Epub 1982/05/01. PubMed PMID: 6122827.
41. Kim H, Pangalis GA, Payne BC, **Kadin ME**, Rappaport H. Ultrastructural identification of neoplastic histiocytes--monocytes: an application of a newly developed cytochemical technique. *Am J Pathol*. 1982;106(2):204-23. Epub 1982/02/01. PubMed PMID: 6950665; PMCID: PMC1916177.
42. Andres TL, **Kadin ME**. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. *Am J Clin Pathol*. 1983;79(5):546-52. Epub 1983/05/01. PubMed PMID: 6188365.
43. Corwin DJ, **Kadin ME**, Andres TL. T cell prolymphocytic leukemia. 2 cases having a postthymic helper phenotype with complement receptors and 14q+ chromosome

- abnormality. *Acta Haematol.* 1983;70(1):43-9. Epub 1983/01/01. doi: 10.1159/000206687. PubMed PMID: 6223478
44. **Kadin ME**, Berard CW, Nanba K, Wakasa H. Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States--Japan seminar, September 6 and 7, 1982, in Seattle, Washington. *Hum Pathol.* 1983;14(9):745-72. Epub 1983/09/01. PubMed PMID: 6350154.
45. Kamoun M, Martin PJ, **Kadin ME**, Lum LG, Hansen JA. Human monocyte-histiocyte differentiation antigens identified by monoclonal antibodies. *Clin Immunol Immunopathol.* 1983;29(2):181-95. Epub 1983/11/01. PubMed PMID: 6414749.
46. Starkebaum G, Martin PJ, Singer JW, Lum LG, Price TH, **Kadin ME**, Raskind WH, Fialkow PJ. Chronic lymphocytosis with neutropenia: evidence for a novel, abnormal T-cell population associated with antibody-mediated neutrophil destruction. *Clin Immunol Immunopathol.* 1983;27(1):110-23. Epub 1983/04/01. PubMed PMID: 6603312.
47. Sullivan KM, Neiman PE, **Kadin ME**, Dahlberg S, Farewell VT, Rudolph RH, Bagley CM, Jr., Appelbaum FR, Thomas ED. Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. *Blood.* 1983;62(1):51-61. Epub 1983/07/01. PubMed PMID: 6344932.
48. Burstein SA, Malpass TW, Yee E, **Kadin M**, Brigden M, Adamson JW, Harker LA. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. *Br J Haematol.* 1984;57(3):383-92. Epub 1984/07/01. PubMed PMID: 6743563.
49. **Kadin ME**, Nasu K, Sako D, Su IJ. Distinctive phorbol ester-induced morphological and surface antigen changes in mycosis fungoides, the Sezary syndrome, and adult T-cell leukemia. *Cancer Res.* 1984;44(8):3383-7. Epub 1984/08/01. PubMed PMID: 6611200
50. Mori N, Tsunoda R, Kojima M, Andres T, **Kadin ME**. Ultrastructural localization of immunoglobulins in hairy cell leukemia. *Hum Pathol.* 1984;15(11):1042-7. Epub 1984/11/01. PubMed PMID: 6436166.
51. Bolen JW, **Kadin ME**. Cutaneous T-cell lymphoma with Reed-Sternberg cells: a light microscopic, immunocytochemical, and ultrastructural study. *Ultrastruct Pathol.* 1985;9(3-4):225-31. Epub 1985/01/01. PubMed PMID: 3879027.
52. Foucar K, Carroll TJ, Jr., Tannous R, Peterson L, Goeken JA, Binion S, Gajl-Peczalska J, **Kadin ME**, Yokoyama WM. Nonendemic adult T-cell leukemia/lymphoma in the United States: report of two cases and review of the literature. *Am J Clin Pathol.* 1985;83(1):18-26. Epub 1985/01/01. PubMed PMID: 2981466.
53. **Kadin M**, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. *Am J Pathol.* 1985;119(2):315-25. Epub 1985/05/01. PubMed PMID: 3158209; PMCID: PMC1887890.
54. **Kadin ME**. Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides, and some types of Hodgkin's disease. *Lancet.* 1985;2(8460):864-5. Epub 1985/10/19. PubMed PMID: 2413323.
55. Loughran TP, Jr., **Kadin ME**, Starkebaum G, Abkowitz JL, Clark EA, Disteché C, Lum LG, Slichter SJ. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. *Ann Intern Med.* 1985;102(2):169-75. Epub 1985/02/01. PubMed PMID: 3966754.
56. McDonald GB, Schuffler MD, **Kadin ME**, Tytgat GN. Intestinal pseudoobstruction caused by diffuse lymphoid infiltration of the small intestine. *Gastroenterology.* 1985;89(4):882-9. Epub 1985/10/01. PubMed PMID: 4029567.

57. Nasu K, Said J, Vonderheid E, Olerud J, Sako D, **Kadin M**. Immunopathology of cutaneous T-cell lymphomas. *Am J Pathol*. 1985;119(3):436-47. Epub 1985/06/01. PubMed PMID: 3893149; PMCID: PMC1888020.
58. Ree HJ, **Kadin ME**. Lectin distinction of benign from malignant histiocytes. *Cancer*. 1985;56(8):2046-50. Epub 1985/10/15. PubMed PMID: 2411387.
59. Ree HJ, **Kadin ME**. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. *Cancer*. 1985;56(2):333-8. Epub 1985/07/15. PubMed PMID: 2408733.
60. Su IJ, Shih LY, **Kadin ME**, Dun P, Hsu SM. Pathologic and immunologic characterization of malignant lymphoma in Taiwan. With special reference to retrovirus-associated adult T-cell lymphoma/leukemia. *Am J Clin Pathol*. 1985;84(6):715-23. Epub 1985/12/01. PubMed PMID: 3000162.
61. Wallis WJ, Loughran TP, Jr., **Kadin ME**, Clark EA, Starkebaum GA. Polyarthritis and neutropenia associated with circulating large granular lymphocytes. *Ann Intern Med*. 1985;103(3):357-62. Epub 1985/09/01. PubMed PMID: 4026084.
62. Abkowitz JL, **Kadin ME**, Powell JS, Adamson JW. Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. *Br J Haematol*. 1986;63(1):59-67. Epub 1986/05/01. PubMed PMID: 3085703.
63. Abkowitz JL, Powell JS, Nakamura JM, **Kadin ME**, Adamson JW. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. *Am J Hematol*. 1986;23(4):363-71. Epub 1986/12/01. PubMed PMID: 3098093.
64. **Kadin ME**. Characteristic immunologic profile of large atypical cells in lymphomatoid papulosis. Possible implications for histogenesis and relationship to other diseases. *Arch Dermatol*. 1986;122(12):1388-90. Epub 1986/12/01. PubMed PMID: 3024585.
65. **Kadin ME**, Sako D, Berliner N, Franklin W, Woda B, Borowitz M, Ireland K, Schweid A, Herzog P, Lange B, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. *Blood*. 1986;68(5):1042-9. Epub 1986/11/01. PubMed PMID: 3490284.
66. Loughran TP, Jr., **Kadin ME**, Deeg HJ. T-cell intestinal lymphoma associated with celiac sprue. *Ann Intern Med*. 1986;104(1):44-7. Epub 1986/01/01. PubMed PMID: 3484421.
67. Ree HJ, **Kadin ME**. Peanut agglutinin. A useful marker for histiocytosis X and interdigitating reticulum cells. *Cancer*. 1986;57(2):282-7. Epub 1986/01/15. PubMed PMID: 2417675.
68. Yim M, Hayashi T, Yanagihara E, **Kadin M**, Nakamura J. HTLV-I-associated T-cell leukemia in Hawaii. *Am J Med Sci*. 1986;292(5):325-7. Epub 1986/11/01. PubMed PMID: 2877581.
69. Agnarsson BA, **Kadin ME**. An unusual B-cell lymphoma simulating hairy cell leukemia. *Am J Clin Pathol*. 1987;88(6):752-9. Epub 1987/12/01. PubMed PMID: 3500633.
70. Head DR, Kjeldsberg CR, **Kadin ME**, Pick T, Bybee B, Longbotham J, Shumski E. Childhood T-cell malignancy resembling adult T-cell leukemia/lymphoma. *Hematol Pathol*. 1987;1(1):15-25. Epub 1987/01/01. PubMed PMID: 3504428.
71. **Kadin ME**. Histogenesis of Hodgkin's disease: possible insights from a comparison with lymphomatoid papulosis. *Hum Pathol*. 1987;18(11):1085-8. Epub 1987/11/01. PubMed PMID: 3500105.
72. **Kadin ME**. Cutaneous Ki-1 lymphoma: pathology, immunology and clinical characteristics. *Princess Takamatsu Symp*. 1987;18:187-95. Epub 1987/01/01. PubMed PMID: 3506541.
73. **Kadin ME**, Vonderheid EC, Sako D, Clayton LK, Olbricht S. Clonal composition of T cells in lymphomatoid papulosis. *Am J Pathol*. 1987;126(1):13-7. Epub 1987/01/01. PubMed PMID: 3544850; PMCID: PMC1899539.

74. Loughran TP, Jr., Starkebaum G, Clark E, Wallace P, **Kadin ME**. Evaluation of splenectomy in large granular lymphocyte leukaemia. *Br J Haematol.* 1987;67(2):135-40. Epub 1987/10/01. PubMed PMID: 3479187.
75. Muramoto LM, **Kadin ME**. Improved detection of lymphoid cell surface antigens in tissues fixed in periodate-lysine-paraformaldehyde (PLP). *Am J Clin Pathol.* 1987;88(5):589-95. Epub 1987/11/01. PubMed PMID: 2823597.
76. Picker LJ, Furst A, Robinson SH, **Kadin ME**. Immunoarchitecture of the bone marrow in neutropenia: increased HNK-1 + cells define a subset of neutropenic patients. *Am J Hematol.* 1987;25(1):29-41. Epub 1987/05/01. PubMed PMID: 3578262.
77. Ree HJ, **Kadin ME**. The usefulness of peanut agglutinin for the detection of histiocytosis-X and interdigitating reticulum cells. *Hum Pathol.* 1987;18(3):309-10. Epub 1987/03/01. PubMed PMID: 3493200.
78. Soff GA, **Kadin ME**. Tocainide-induced reversible agranulocytosis and anemia. *Arch Intern Med.* 1987;147(3):598-9. Epub 1987/03/01. PubMed PMID: 3103562.
79. **Kadin ME**. Characteristic immunologic profile of large atypical cells in lymphomatoid papulosis. Possible implications for histogenesis and relationship to other diseases. *Arch Dermatol.* 1986;122(12):1388-90. Epub 1986/12/01. PubMed PMID: 3024585.
80. **Kadin ME**, Sako D, Berliner N, Franklin W, Woda B, Borowitz M, Ireland K, Schweid A, Herzog P, Lange B, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. *Blood.* 1986;68(5):1042-9. Epub 1986/11/01. PubMed PMID: 3490284.
81. Loughran TP, Jr., **Kadin ME**, Deeg HJ. T-cell intestinal lymphoma associated with celiac sprue. *Ann Intern Med.* 1986;104(1):44-7. Epub 1986/01/01. PubMed PMID: 3484421.
82. Ree HJ, **Kadin ME**. Peanut agglutinin. A useful marker for histiocytosis X and interdigitating reticulum cells. *Cancer.* 1986;57(2):282-7. Epub 1986/01/15. PubMed PMID: 2417675.
83. Yim M, Hayashi T, Yanagihara E, **Kadin M**, Nakamura J. HTLV-I-associated T-cell leukemia in Hawaii. *Am J Med Sci.* 1986;292(5):325-7. Epub 1986/11/01. PubMed PMID: 2877581.
84. Agnarsson BA, **Kadin ME**. An unusual B-cell lymphoma simulating hairy cell leukemia. *Am J Clin Pathol.* 1987;88(6):752-9. Epub 1987/12/01. PubMed PMID: 3500633.
85. Head DR, Kjeldsberg CR, **Kadin ME**, Pick T, Bybee B, Longbotham J, Shumski E. Childhood T-cell malignancy resembling adult T-cell leukemia/lymphoma. *Hematol Pathol.* 1987;1(1):15-25. Epub 1987/01/01. PubMed PMID: 3504428.
86. **Kadin ME**. Histogenesis of Hodgkin's disease: possible insights from a comparison with lymphomatoid papulosis. *Hum Pathol.* 1987;18(11):1085-8. Epub 1987/11/01. PubMed PMID: 3500105.
87. **Kadin ME**. Cutaneous Ki-1 lymphoma: pathology, immunology and clinical characteristics. *Princess Takamatsu Symp.* 1987;18:187-95. Epub 1987/01/01. PubMed PMID: 3506541.
88. **Kadin ME**, Vonderheid EC, Sako D, Clayton LK, Olbricht S. Clonal composition of T cells in lymphomatoid papulosis. *Am J Pathol.* 1987;126(1):13-7. Epub 1987/01/01. PubMed PMID: 3544850; PMCID: PMC1899539.
89. Loughran TP, Jr., Starkebaum G, Clark E, Wallace P, **Kadin ME**. Evaluation of splenectomy in large granular lymphocyte leukaemia. *Br J Haematol.* 1987;67(2):135-40. Epub 1987/10/01. PubMed PMID: 3479187.
90. Muramoto LM, **Kadin ME**. Improved detection of lymphoid cell surface antigens in tissues fixed in periodate-lysine-paraformaldehyde (PLP). *Am J Clin Pathol.* 1987;88(5):589-95. Epub 1987/11/01. PubMed PMID: 2823597.

91. Picker LJ, Furst A, Robinson SH, **Kadin ME**. Immunoarchitecture of the bone marrow in neutropenia: increased HNK-1 + cells define a subset of neutropenic patients. *Am J Hematol.* 1987;25(1):29-41. Epub 1987/05/01. PubMed PMID: 3578262.
92. Ree HJ, **Kadin ME**. The usefulness of peanut agglutinin for the detection of histiocytosis-X and interdigitating reticulum cells. *Hum Pathol.* 1987;18(3):309-10. Epub 1987/03/01. PubMed PMID: 3493200.
93. Soff GA, **Kadin ME**. Tocainide-induced reversible agranulocytosis and anemia. *Arch Intern Med.* 1987;147(3):598-9. Epub 1987/03/01. PubMed PMID: 3103562.
94. Starkebaum G, Loughran TP, Jr., Kalyanaraman VS, **Kadin ME**, Kidd PG, Singer JW, Ruscetti FW. Serum reactivity to human T-cell leukaemia/lymphoma virus type I proteins in patients with large granular lymphocytic leukaemia. *Lancet.* 1987;1(8533):596-9. Epub 1987/03/14. PubMed PMID: 2881134.
95. Agnarsson BA, **Kadin ME**. Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. *Am J Surg Pathol.* 1988;12(4):264-74. Epub 1988/04/01. PubMed PMID: 3354752.
96. Aozasa K, Ueda T, Kurata A, Kim CW, Inoue M, Matsuura N, Takeuchi T, Tsujimura T, **Kadin ME**. Prognostic value of histologic and clinical factors in 56 patients with gastrointestinal lymphomas. *Cancer.* 1988;61(2):309-15. Epub 1988/01/15. PubMed PMID: 3334966.
97. **Kadin ME**, Muramoto L, Said J. Expression of T-cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease. *Am J Pathol.* 1988;130(2):345-53. Epub 1988/02/01. PubMed PMID: 2963547; PMID: PMC1880530.
98. **Kadin ME**, Said J. T-cell lymphomas and leukemias of post-thymic differentiation. *Clin Lab Med.* 1988;8(1):135-50. Epub 1988/03/01. PubMed PMID: 2896086.
99. Newcom SR, **Kadin ME**, Ansari AA. Production of transforming growth factor-beta activity by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth. *Am J Pathol.* 1988;131(3):569-77. Epub 1988/06/01. PubMed PMID: 2898211; PMID: PMC1880714.
100. Newcom SR, **Kadin ME**, Ansari AA, Diehl V. L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. *J Clin Invest.* 1988;82(6):1915-21. Epub 1988/12/01. doi: 10.1172/JCI113810. PubMed PMID: 2904450; PMID: PMC442772.
101. Newcom SR, **Kadin ME**, Phillips C. L-428 Reed-Sternberg cells and mononuclear Hodgkin's cells arise from a single cloned mononuclear cell. *Int J Cell Cloning.* 1988;6(6):417-31. Epub 1988/11/01. doi: 10.1002/stem.5530060606. PubMed PMID: 3230329.
102. Su IJ, Balk SP, **Kadin ME**. Molecular basis for the aberrant expression of T cell antigens in postthymic T cell malignancies. *Am J Pathol.* 1988;132(2):192-8. Epub 1988/08/01. PubMed PMID: 2456698; PMID: PMC1880737.
103. Agnarsson BA, **Kadin ME**. Host response in lymphomatoid papulosis. *Hum Pathol.* 1989;20(8):747-52. Epub 1989/08/01. PubMed PMID: 2787272.
104. Agnarsson BA, **Kadin ME**. The immunophenotype of Reed-Sternberg cells. A study of 50 cases of Hodgkin's disease using fixed frozen tissues. *Cancer.* 1989;63(11):2083-7. Epub 1989/06/01. PubMed PMID: 2566368.
105. Agnarsson BA, Loughran TP, Jr., Starkebaum G, **Kadin ME**. The pathology of large granular lymphocyte leukemia. *Hum Pathol.* 1989;20(7):643-51. Epub 1989/07/01. PubMed PMID: 2661408.

106. Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, **Kadin ME**, Vardiman JW. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. *Leukemia*. 1989;3(12):866-70. Epub 1989/12/01. PubMed PMID: 2555633.
107. Safian RD, Come SE, **Kadin M**, Lorell BH. Use of pulmonarycapillary wedge aspirates for the antemortem diagnosis of pulmonary microvascular tumor. *Cathet Cardiovasc Diagn*. 1989;17(2):112-5. Epub 1989/06/01. PubMed PMID: 2720771.
108. Sharpe RJ, **Kadin ME**, Harmon DC, Imber MJ, Anderson RR. Complete resolution of Kaposi's sarcoma with systemic etretinate therapy in a patient with mycosis fungoides. *J Am Acad Dermatol*. 1989;20(6):1123-4. Epub 1989/06/01. PubMed PMID: 2754062.
109. Su IJ, **Kadin ME**. Expression of growth factor/receptor genes in postthymic T cell malignancies. *Am J Pathol*. 1989;135(3):439-45. Epub 1989/09/01. PubMed PMID: 2789474; PMCID: PMC1879862.
110. Vonderheid EC, Bigler RD, Rogers TJ, **Kadin ME**, Griffin TD. Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris. *Yale J Biol Med*. 1989;62(6):653-64. Epub 1989/11/01. PubMed PMID: 2636805; PMCID: PMC2589147.
111. Agnarsson BA, Vonderheid EC, **Kadin ME**. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. *J Am Acad Dermatol*. 1990;22(4):569-77. Epub 1990/04/01. PubMed PMID: 2138636.
112. **Kadin ME**. The Reed-Sternberg cell, an activated T-cell? The evidence has come full circle. *Leuk lymphoma*. 1990;2(5):279-86. Epub 1990/01/01. doi: 10.3109/10428199009106462. PubMed PMID: 27456917.
113. **Kadin ME**. The spectrum of Ki-1+ cutaneous lymphomas. *Curr Probl Dermatol*. 1990;19:132-43. Epub 1990/01/01. PubMed PMID: 2153504.
114. **Kadin ME**, Agnarsson BA, Ellingsworth LR, Newcom SR. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. *Am J Pathol*. 1990;136(6):1209-14. Epub 1990/06/01. PubMed PMID: 2356855; PMCID: PMC1877568.
115. **Kadin ME**, Said JW. Pathology of malignant lymphomas. *Curr Opin Oncol*. 1990;2(5):822-31. Epub 1990/10/01. PubMed PMID: 1965694.
116. **Kadin MR**. Radiation vs surgery for brain metastases. *Oncology (Williston Park)*. 1990;4(2):19. Epub 1990/02/01. PubMed PMID: 2143664.
117. Su IJ, Wu YC, Chen YC, Hsieh HC, Cheng AL, Wang CH, **Kadin ME**. Cutaneous manifestations of postthymic T cell malignancies: description of five clinicopathologic subtypes. *J Am Acad Dermatol*. 1990;23(4 Pt 1):653-62. Epub 1990/10/01. PubMed PMID: 2229493.
118. Varga FJ, Vonderheid EC, Olbricht SM, **Kadin ME**. Immunohistochemical distinction of lymphomatoid papulosis and pityriasis lichenoides et varioliformis acuta. *Am J Pathol*. 1990;136(4):979-87. Epub 1990/04/01. PubMed PMID: 1691596; PMCID: PMC1877642.
119. Vonderheid EC, Kang CA, **Kadin M**, Bigler RD, Griffin TD, Rogers TJ. Extracorporeal photopheresis in psoriasis vulgaris: clinical and immunologic observations. *J Am Acad Dermatol*. 1990;23(4 Pt 1):703-12. Epub 1990/10/01. PubMed PMID: 2229499.
120. Agnarsson BA, Vonderheid EC, **Kadin ME**. CD8+ cutaneous T-cell lymphoma. *Am J Dermatopathol*. 1991;13(6):628-9. Epub 1991/12/01. PubMed PMID: 1805657.
121. Goldman BD, Bari M, Kantor GR, **Kadin ME**, Micaily B, Vonderheid EC. Cutaneous multilobated T-cell lymphoma with aggressive course. *J Am Acad Dermatol*. 1991;25(2 Pt 2):345-9. Epub 1991/08/01. PubMed PMID: 1894770.

122. **Kadin ME.** Unexpected finding--biologic truth or technical artifact? *Hum Pathol.* 1991;22(10):941-3. Epub 1991/10/01. PubMed PMID: 1842382.
123. **Kadin ME.** Lymphomatoid papulosis, Ki-1+ lymphoma, and primary cutaneous Hodgkin's disease. *Semin Dermatol.* 1991;10(3):164-71. Epub 1991/09/01. PubMed PMID: 1657104.
124. **Kadin ME.** Ki-1-positive anaplastic large-cell lymphoma: a clinicopathologic entity? *J Clin Oncol.* 1991;9(4):533-6. Epub 1991/04/01. doi: 10.1200/JCO.1991.9.4.533. PubMed PMID: 1648595.
125. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, Herin M, Noel H, **Kadin M**, Mueller-Hermelink HK, Van Snick J, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. *Blood.* 1991;78(5):1311-7. Epub 1991/09/01. PubMed PMID: 1908723.
126. Su IJ, Hsieh HC, Lin KH, Uen WC, Kao CL, Chen CJ, Cheng AL, **Kadin ME**, Chen JY. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. *Blood.* 1991;77(4):799-808. Epub 1991/02/15. PubMed PMID: 1847084.
127. Davis TH, Morton CC, Miller-Cassman R, Balk SP, **Kadin ME.** Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. *N Engl J Med.* 1992;326(17):1115-22. Epub 1992/04/23. doi: 10.1056/NEJM199204233261704. PubMed PMID: 1532439.
128. Hsu WT, Toporcer MB, Kantor GR, Vonderheid EC, **Kadin ME.** Cutaneous T-cell lymphoma with porokeratosis-like lesions. *J Am Acad Dermatol.* 1992;27(2 Pt 2):327-30. Epub 1992/08/01. PubMed PMID: 1517498.
129. Newcom SR, Tagra KK, **Kadin ME.** Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta. *Am J Pathol.* 1992;140(3):709-18. Epub 1992/03/01. PubMed PMID: 1312308; PMCID: PMC1886176.
130. Olerud JE, Kulin PA, Chew DE, Carlsen RA, Hammar SP, Weir TW, Patterson SD, Bolen JW, **Kadin ME**, Barker E, et al. Cutaneous T-cell lymphoma. Evaluation of pretreatment skin biopsy specimens by a panel of pathologists. *Arch Dermatol.* 1992;128(4):501-7. Epub 1992/04/01. PubMed PMID: 1580657.
131. Sioutos N, **Kadin ME.** Perivascular Ki-1 + lesions. *Int J Hematol.* 1992;55(3):275-9. Epub 1992/06/01. PubMed PMID: 1498318.
132. Wang HH, Lach L, **Kadin ME.** Epidemiology of lymphomatoid papulosis. *Cancer.* 1992;70(12):2951-7. Epub 1992/12/15. PubMed PMID: 1451079.
133. Goldman BD, Oh SK, Davis BE, **Kadin ME**, Poiesz BJ, Koh HK. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment. *Arch Dermatol.* 1993;129(9):1166-70. Epub 1993/09/01. PubMed PMID: 8363402.
134. **Kadin M**, Butmarc J, Elovic A, Wong D. Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease. *Am J Pathol.* 1993;142(1):11-6. Epub 1993/01/01. PubMed PMID: 8424449; PMCID: PMC1886832.
135. **Kadin ME.** Lymphomatoid papulosis and associated lymphomas. How are they related? *Arch Dermatol.* 1993;129(3):351-3. Epub 1993/03/01. PubMed PMID: 8447675.
136. **Kadin ME**, Vonderheid EC, Weiss LM. Absence of Epstein-Barr viral RNA in lymphomatoid papulosis. *J Pathol.* 1993;170(2):145-8. Epub 1993/06/01. doi: 10.1002/path.1711700208. PubMed PMID: 8393923.
137. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, **Kadin ME.** A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. *Am J Surg Pathol.* 1993;17(9):859-68. Epub 1993/09/01. PubMed PMID: 8394652.

138. Mauch PM, Kalish LA, **Kadin M**, Coleman CN, Osteen R, Hellman S. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. *Cancer*. 1993;71(6):2062-71. Epub 1993/03/15. PubMed PMID: 8443755.
139. Volkenandt M, Bertino JR, Shenoy BV, Koch OM, **Kadin ME**. Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma. *J Dermatol Sci*. 1993;6(2):121-6. Epub 1993/10/01. PubMed PMID: 8274457.
140. Finlay JL, Anderson JR, Cecalupo AJ, Hutchinson RJ, **Kadin ME**, Kjeldsberg CR, Provisor AJ, Woods WG, Meadows AT. Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552. *Med Pediatr Oncol*. 1994;23(6):453-63. Epub 1994/01/01. PubMed PMID: 7935170.
141. Wasik MA, Sioutus N, Tuttle M, Butmarc JR, Kaplan WD, **Kadin ME** Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice. *Am J Pathol*. 1994 May; 144(5): 1089-1097.
142. **Kadin ME**. Pathology of Hodgkin's disease. *Curr Opin Oncol*. 1994;6(5):456-63. Epub 1994/09/01. PubMed PMID: 7827147.
143. **Kadin ME**. Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy. *J Clin Oncol*. 1994;12(5):884-7. Epub 1994/05/01. doi: 10.1200/JCO.1994.12.5.884. PubMed PMID: 8164037.
144. **Kadin ME**. Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. *Ann Oncol*. 1994;5 Suppl 1:25-30. Epub 1994/01/01. PubMed PMID: 8172812
145. Cohen PL, Butmarc J, **Kadin ME**. Expression of Hodgkin's disease associated antigen BLA.36 in anaplastic large cell lymphomas and lymphomatoid papulosis primarily of T-cell origin. *Am J Clin Pathol*. 1995;104(1):50-3. Epub 1995/07/01. PubMed PMID: 7611181.
146. DeCoteau JF, **Kadin ME**. New insights into peripheral T-cell lymphomas. *Curr Opin Oncol*. 1995;7(5):408-14. Epub 1995/09/01. PubMed PMID: 8541384.
147. Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, **Kadin ME**. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. *Blood*. 1995;85(8):2139-46. Epub 1995/04/15. PubMed PMID: 7718885.
148. Peters K, Knoll JH, **Kadin ME**. Cytogenetic findings in regressing skin lesions of lymphomatoid papulosis. *Cancer Genet Cytogenet*. 1995;80(1):13-6. Epub 1995/03/01. PubMed PMID: 7697626.
149. Piira T, Perkins SL, Anderson JR, Meadows AT, Chilcote RR, **Kadin M**, Kjeldsberg CR. Primary mediastinal large cell lymphoma in children: a report from the Childrens Cancer Group. *Pediatr Pathol Lab Med*. 1995;15(4):561-70. Epub 1995/07/01. PubMed PMID: 8597843.
150. Resnik KS, Kantor GR, Lessin SR, **Kadin ME**, Chooback L, Cooper HS, Vonderheid EC. Mycosis fungoides palmaris et plantaris. *Arch Dermatol*. 1995;131(9):1052-6. Epub 1995/09/01. PubMed PMID: 7661607.
151. Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, **Kadin M**, Morse M, King D, Steinherz PG, Kersey JH. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. *J Clin Oncol*. 1995;13(6):1368-76. Epub 1995/06/01. doi: 10.1200/JCO.1995.13.6.1368. PubMed PMID: 7751881
152. Zirbel GM, Gellis SE, **Kadin ME**, Esterly NB. Lymphomatoid papulosis in children. *J Am Acad Dermatol*. 1995;33(5 Pt 1):741-8. Epub 1995/11/01. PubMed PMID: 7593772.

153. Wasik MA, Sackstein R, Novick D, Butmarc JR, Vonderheid EC, Kadin ME. Cutaneous CD56+ large (T-) cell lymphoma associated with high concentration of serum IL-2. *Human Pathology*, 27:738-44, 1996.
154. Chott A, Vonderheid EC, Olbricht S, Miao NN, Balk SP, **Kadin ME**. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. *J Invest Dermatol*. 1996;106(4):696-700. Epub 1996/04/01. PubMed PMID: 8618007.
155. Crowson AN, Magro CM, **Kadin ME**, Stranc M. Differential expression of the bcl-2 oncogene in human basal cell carcinoma. *Hum Pathol*. 1996;27(4):355-9. Epub 1996/04/01. PubMed PMID: 8617478.
156. DeCoteau JF, Butmarc JR, Kinney MC, **Kadin ME**. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. *Blood*. 1996;87(8):3437-41. Epub 1996/04/15. PubMed PMID: 8605362.
157. Gruss HJ, **Kadin ME**. Pathophysiology of Hodgkin's disease: functional and molecular aspects. *Baillieres Clin Haematol*. 1996;9(3):417-46. Epub 1996/09/01. PubMed PMID: 8922238.
158. Gruss HJ, Pinto A, Gloghini A, Wehnes E, Wright B, Boiani N, Aldinucci D, Gattei V, Zagonel V, Smith CA, **Kadin ME**, von Schilling C, Goodwin RG, Herrmann F, Carbone A. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. *Am J Pathol*. 1996;149(2):469-81. Epub 1996/08/01. PubMed PMID: 8701986; PMCID: PMC1865328.
159. Ichinohasama R, Endoh K, Ishizawa K, Okuda M, Kameoka J, Meguro K, Myers J, **Kadin ME**, Mori S, Sawai T. Thymic lymphoblastic lymphoma of committed natural killer cell precursor origin: a case report. *Cancer*. 1996;77(12):2592-603. Epub 1996/06/15. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2592::AID-CNCR25>3.0.CO;2-M. PubMed PMID: 8640711.
160. Ichinohasama R, Miura I, Takahashi T, Yaginuma Y, Myers J, DeCoteau JF, Yee C, **Kadin ME**, Mori S, Sawai T. Peripheral CD4+ CD8- gammadelta T cell lymphoma: a case report with multiparameter analyses. *Hum Pathol*. 1996;27(12):1370-7. Epub 1996/12/01. PubMed PMID: 8958314.
161. Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M, **Kadin ME**, Lodish HF. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. *Mol Cell Biol*. 1996;16(7):3480-9. Epub 1996/07/01. PubMed PMID: 8668164; PMCID: PMC231343.
162. Marti RM, Wasik MA, **Kadin ME**. Constitutive secretion of GM-CSF by three different cell lines derived from a single patient with a progressive cutaneous lymphoproliferative disorder. *Cytokine*. 1996;8(4):323-9. Epub 1996/04/01. doi: 10.1006/cyto.1996.0044. PubMed PMID: 9162223.
163. Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, **Kadin M**, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. *Br J Haematol*. 1996;92(4):872-9. Epub 1996/03/01. PubMed PMID: 8616080.
164. Vonderheid EC, Sajjadian A, **Kadin ME**. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. *J Am Acad Dermatol*. 1996;34(3):470-81. Epub 1996/03/01. PubMed PMID: 8609262.

165. Wasik MA, Sackstein R, Novick D, Butmarc JR, Zhang Q, Vonderheid EC, **Kadin ME**. Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2. *Hum Pathol*. 1996;27(7):738-44. Epub 1996/07/01. PubMed PMID: 8698322.
166. Wasik MA, Seldin DC, Butmarc JR, Gertz R, Marti R, Maslinski W, **Kadin ME**. Analysis of IL-2, IL-4 and their receptors in clonally-related cell lines derived from a patient with a progressive cutaneous T-cell lymphoproliferative disorder. *Leuk Lymphoma*. 1996;23(1-2):125-36. Epub 1996/09/01. doi: 10.3109/10428199609054811. PubMed PMID: 9021695.
167. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, **Kadin ME**. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. *Arch Dermatol*. 1996;132(1):42-7. Epub 1996/01/01. PubMed PMID: 8546482.
168. Zhang Q, Nowak I, Vonderheid EC, Rook AH, **Kadin ME**, Nowell PC, Shaw LM, Wasik MA. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. *Proc Natl Acad Sci U S A*. 1996;93(17):9148-53. Epub 1996/08/20. PubMed PMID: 8799169; PMCID: PMC38610.
169. Ichinohasama R, Miura I, Takahashi T, Yaginuma U, Myers J, De Coteau JF, Yee C, **Kadin ME**, Mori S, Sawai T. Peripheral CD4+ CD8- $\gamma\delta$ T cell lymphoma: A case report with multiparameter analysis. *Human Pathology* 27:1370-77, 1996.
170. Bodis S, Kraus MD, Pinkus G, Silver B, **Kadin ME**, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. *J Clin Oncol*. 1997;15(9):3060-6. Epub 1997/09/19. doi: 10.1200/JCO.1997.15.9.3060. PubMed PMID: 9294468.
171. Butmarc J, Kourea HP, **Kadin ME**. CD5 immunostaining of lymphoid neoplasms in paraffin sections. *Am J Clin Pathol*. 1997;107(4):496-7; author reply 7. Epub 1997/04/01. PubMed PMID: 9124221.
172. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, **Kadin ME**. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A*. 1997;94(11):5877-81. Epub 1997/05/27. PubMed PMID: 9159168; PMCID: PMC20874.
173. Demierre MF, Goldberg LJ, **Kadin ME**, Koh HK. Is it lymphoma or lymphomatoid papulosis? *J Am Acad Dermatol*. 1997;36(5 Pt 1):765-72. Epub 1997/05/01. PubMed PMID: 9146539.
174. Ichinohasama R, DeCoteau JF, Myers J, **Kadin ME**, Sawai T, Ooya K. Three-color flow cytometry in the diagnosis of malignant lymphoma based on the comparative cell morphology of lymphoma cells and reactive lymphocytes. *Leukemia*. 1997;11(11):1891-903. Epub 1997/11/22. PubMed PMID: 9369423.
175. **Kadin ME**. Anaplastic large cell lymphoma and its morphological variants. *Cancer Surv*. 1997;30:77-86. Epub 1997/01/01. PubMed PMID: 9547987.
176. Lay JD, Tsao CJ, Chen JY, **Kadin ME**, Su IJ. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. *J Clin Invest*. 1997;100(8):1969-79. Epub 1997/10/23. doi: 10.1172/JCI119728. PubMed PMID: 9329960; PMCID: PMC508386.
177. Lowsky R, DeCoteau JF, Reitmair AH, Ichinohasama R, Dong WF, Xu Y, Mak TW, **Kadin ME**, Minden MD. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of rhombotin-2 (Lmo-2) and Tal-1 (SCL). *Blood*. 1997;89(7):2276-82. Epub 1997/04/01. PubMed PMID: 9116269.

178. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, **Kadin ME**, Cabanillas F, Andreeff M, Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. *Br J Haematol.* 1997;99(3):618-24. Epub 1997/12/24. PubMed PMID: 9401075.
179. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, 3rd, **Kadin M**, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. *Biol Blood Marrow Transplant.* 1997;3(2):98-106. Epub 1997/06/01. PubMed PMID: 9267670.
180. Bhattacharyya N, Frankenthaler RA, Gomolin HI, **Kadin ME**, Lauretano AM. Clinical and pathologic characterization of mucosa-associated lymphoid tissue lymphoma of the head and neck. *Ann Otol Rhinol Laryngol.* 1998;107(9 Pt 1):801-6. Epub 1998/09/28. doi: 10.1177/000348949810700912. PubMed PMID: 9749552.
181. Butmarc JR, Kourea HP, Levi E, **Kadin ME**. Improved detection of CD5 epitope in formalin-fixed paraffin-embedded sections of benign and neoplastic lymphoid tissues by using biotinylated tyramine enhancement after antigen retrieval. *Am J Clin Pathol.* 1998;109(6):682-8. Epub 1998/06/10. PubMed PMID: 9620024.
182. Dubin DB, Hurowitz JC, Brettler D, Bernhard JD, **Kadin ME**, Wallace JE, Woda B, Pihan G, Kupper TS, Harrist TJ. Adnexotropic T-cell lymphoma presenting with generalized anhidrosis, progressive alopecia, pruritus, and Sjogren's syndrome. *J Am Acad Dermatol.* 1998;38(3):493-7. Epub 1998/03/31. PubMed PMID: 9520037.
183. Ichinohasama R, Miura I, Funato T, Sato I, Suzuki C, Saito Y, Decoteau JF, Myers JB, **Kadin ME**, Sawai T, Ooya K. A recurrent nonrandom translocation (3;7)(q27;p12) associated with BCL-6 gene rearrangement in B-cell diffuse large cell lymphoma. *Cancer Genet Cytogenet.* 1998;104(1):19-27. Epub 1998/07/02. PubMed PMID: 9648553.
184. Ichinohasama R, Miura I, Kobayashi N, Saitoh Y, DeCoteau JF, Saiki Y, Mori S, **Kadin ME**, Ooya K. Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. *Am J Surg Pathol.* 1998;22(12):1528-37. Epub 1998/12/16. PubMed PMID: 9850179.
185. Ichinohasama R, Miura I, Shishido T, Matsumoto K, Shimizu Y, Miki T, DeCoteau JF, **Kadin ME**, Ooya K. Translocation (3;16)(q27;p11) in a patient with diffuse large B-cell lymphoma associated with the BCL-6 gene rearrangement. *Cancer Genet Cytogenet.* 1998;103(2):133-9. Epub 1998/06/06. PubMed
186. **Kadin ME**, Morris SW. The t(2;5) in human lymphomas. *Leuk Lymphoma.* 1998;29(3-4):249-56. Epub 1998/07/31. doi: 10.3109/10428199809068562. PubMed PMID: 9684923.
187. Ott G, Bastian BC, Katzenberger T, Decoteau JF, Kalla J, Rosenwald A, Weissinger F, Ott MM, **Kadin ME**, Muller-Hermelink HK. A lymphohistiocytic variant of anaplastic large cell lymphoma with demonstration of the t(2;5)(p23;q35) chromosome translocation. *Br J Haematol.* 1998;100(1):187-90. Epub 1998/02/05. PubMed PMID: 9450809.
188. Ott G, Katzenberger T, Siebert R, DeCoteau JF, Fletcher JA, Knoll JH, Kalla J, Rosenwald A, Ott MM, Weber-Matthiesen K, **Kadin ME**, Muller-Hermelink HK. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. *Genes Chromosomes Cancer.* 1998;22(2):114-21. Epub 1998/05/23. PubMed PMID: 9598798.
189. Paulli M, Berti E, Boveri E, Kindl S, Bonoldi E, Gambini C, Rosso R, Borroni G, Straccapansa V, Magrini U, DeCoteau JE, Krammer PH, Moller P, **Kadin ME**. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor

- necrosis factor receptor superfamily. *Hum Pathol.* 1998;29(11):1223-30. Epub 1998/11/21. PubMed PMID: 9824099.
190. Ree HJ, **Kadin ME**, Kikuchi M, Ko YH, Go JH, Suzumiya J, Kim DS. Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers. *Am J Surg Pathol.* 1998;22(6):643-55. Epub 1998/06/18. PubMed PMID: 9630171.
191. Rudiger T, Jaffe ES, Delsol G, deWolf-Peeters C, Gascoyne RD, Georgii A, Harris NL, **Kadin ME**, MacLennan KA, Poppema S, Stein H, Weiss LE, Muller-Hermelink HK. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). *Ann Oncol.* 1998;9 Suppl 5:S31-8. Epub 1999/02/02. PubMed PMID: 9926235.
192. Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, **Kadin ME**, Wheeler C. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. *Blood.* 1998;91(2):717-23. Epub 1998/01/15. PubMed PMID: 9427731.
193. Sleckman BG, Mauch PM, Ambinder RF, Mann R, Pinkus GS, **Kadin ME**, Sherburne B, Perez-Atayde A, Thior I, Mueller N. Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. *Cancer Epidemiol Biomarkers Prev.* 1998;7(12):1117-21. Epub 1998/12/29. PubMed PMID: 9865430.
194. Dubin DB, Hurowitz JC, Brettler D, Bernhard JD, **Kadin ME**, Wallace JE, Woda B, Pihan G, Kupper TS, Harrist TJ. Adnexotropic T-cell lymphoma presenting with generalized anhidrosis, progressive alopecia, pruritis and Sjogren's syndrome. *J Am Acad Dermatol* 38:493-7, 1998.
195. Ichinohasama R, Miura I, Kobayashi N, **Kadin ME**, Ooya K. Herpes virus type 8 negative (HHV8-) primary effusion lymphoma (PEL) with t(9;14) carrying PAX-5 gene rearrangement: report of a human immunodeficiency virus-negative (HIV-) case with hepatitis C virus-associated (HCV+) liver cirrhosis and hepatocellular carcinoma- A case report and proposal of a reorganized concept regarding PEL. *American Journal of Surgical Pathology*, 22:1528-37, 1998
196. Hodges KB, Collins RD, Greer JP, **Kadin ME**, Kinney MC. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: pathologic and clinical features. *Am J Surg Pathol.* 1999;23(1):49-58. Epub 1999/01/15. PubMed PMID: 9888703.
197. Kinney MC, **Kadin ME**. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. *Am J Clin Pathol.* 1999;111(1 Suppl 1):S56-67. Epub 1999/01/23. PubMed PMID: 9894470.
198. Lin BT, Beckwith B, **Kadin ME**. Mediastinal yolk sac tumors. *Am J Surg Pathol.* 1999;23(1):132-3. Epub 1999/01/15. PubMed PMID: 9888715.
199. Mori M, Manuelli C, Pimpinelli N, Mavilia C, Maggi E, Santucci M, Bianchi B, Cappugi P, Giannotti B, **Kadin ME**. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. *Blood.* 1999;94(9):3077-83. Epub 1999/11/11. PubMed PMID: 10556192.
200. Pfeifer W, Levi E, Petrogiannis-Halioitis T, Lehmann L, Wang Z, **Kadin ME**. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). *Am J Pathol.* 1999;155(4):1353-9. Epub 1999/10/09. doi: 10.1016/S0002-9440(10)65237-6. PubMed PMID: 10514417; PMCID: PMC1867013.
201. Ree HJ, **Kadin ME**, Kikuchi M, Ko YH, Suzumiya J, Go JH. Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: heterogeneity of intrafollicular T-cells and their altered

- distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma. *Hum Pathol.* 1999;30(4):403-11. Epub 1999/04/20. PubMed PMID: 10208461.
202. Schieman WP, Pfeifer WM, Levi E, **Kadin ME**, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. *Blood.* 1999;94(8):2854-61. Epub 1999/10/09. PubMed PMID: 10515889.
203. Signoretti S, Murphy M, Cangi MG, Puddu P, **Kadin ME**, Loda M. Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. *Am J Pathol.* 1999;154(1):67-75. Epub 1999/01/23. PubMed PMID: 9916920; PMCID: PMC1853445.
204. Signoretti S, Murphy M, Puddu P, DeCoteau JF, Faraggiana T, **Kadin ME**, Loda M. Clonality of cutaneous B-cell infiltrates determined by microdissection and immunoglobulin gene rearrangement. *Diagn Mol Pathol.* 1999;8(4):176-82. Epub 2000/01/05. PubMed PMID: 10617273.
205. Wang HH, Myers T, Lach LJ, Hsieh CC, **Kadin ME**. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. *Cancer.* 1999;86(7):1240-5. Epub 1999/10/03. PubMed PMID: 10506709.
206. Buckley JD, Meadows AT, **Kadin ME**, Le Beau MM, Siegel S, Robison LL. Pesticide exposures in children with non-Hodgkin lymphoma. *Cancer.* 2000;89(11):2315-21. Epub 2001/01/09. PubMed PMID: 11147603.
207. Dereure O, Levi E, **Kadin ME**. T-Cell clonality in pityriasis lichenoides et varioliformis acuta: a heteroduplex analysis of 20 cases. *Arch Dermatol.* 2000;136(12):1483-6. Epub 2000/12/15. PubMed PMID: 11115158.
208. Drews R, Samel A, **Kadin ME**. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. *Semin Cutan Med Surg.* 2000;19(2):109-17. Epub 2000/07/13. PubMed PMID: 10892712.
209. Ichinohasama R, Miura I, Takahashi N, Sugawara T, Tamate E, Endoh K, Endoh F, Naganuma H, DeCoteau JF, Griffin JD, **Kadin ME**, Ooya K. pH-negative non-Hodgkin's lymphoma occurring in chronic phase of pH-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. *Leukemia.* 2000;14(1):169-82. Epub 2000/01/19. PubMed PMID: 10637493.
210. **Kadin ME**. Cutaneous gamma delta T-cell lymphomas--how and why should they be recognized? *Arch Dermatol.* 2000;136(8):1052-4. Epub 2000/08/05. PubMed PMID: 10926743.
211. **Kadin ME**. Regulation of CD30 antigen expression and its potential significance for human disease. *Am J Pathol.* 2000;156(5):1479-84. Epub 2000/05/04. doi: 10.1016/S0002-9440(10)65018-3. PubMed PMID: 10793058; PMCID: PMC1876905.
212. Kempf W, Margolin DH, Dezube BJ, **Kadin ME**, Letvin NL, Koralknik IJ. Clinicopathological characterization of an HIV-2-infected individual with two clonally unrelated primary lymphomas. *Am J Hematol.* 2000;65(4):302-6. Epub 2000/11/14. PubMed PMID: 11074559.
213. Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R, **Kadin ME**. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. *J Invest Dermatol.* 2000;115(6):1034-40. Epub 2000/12/20. doi: 10.1046/j.1523-1747.2000.00175.x. PubMed PMID: 11121138.
214. Lones MA, Perkins SL, Sposto R, **Kadin ME**, Kjeldsberg CR, Wilson JF, Cairo MS. Large-cell lymphoma arising in the mediastinum in children and adolescents is associated with an

- excellent outcome: a Children's Cancer Group report. *J Clin Oncol.* 2000;18(22):3845-53. Epub 2000/11/15. doi: 10.1200/JCO.2000.18.22.3845. PubMed PMID: 11078498.
215. Lowsky R, Magliocco A, Ichinohasama R, Reitmair A, Scott S, Henry M, **Kadin ME**, DeCoteau JF. MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability. *Blood.* 2000;95(5):1767-72. Epub 2000/02/26. PubMed PMID: 10688836.
216. Murphy M, Signoretti S, **Kadin ME**, Loda M. Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. *J Cutan Pathol.* 2000;27(5):228-34. Epub 2000/06/10. PubMed PMID: 10847547.
217. Kempf W, Margolin DH, Dezube BJ, **Kadin ME**, Letvin NL, Koralnik IJ. Clinicopathologic characterization of an HIV-2-infected patient with two clonally unrelated primary lymphomas. *American Journal of Hematology,* 65:302-306, 2000.
218. Przybylski GK, Wu H, Macon WR, Finan J, Leonard DG, Felgar RE, DiGiuseppe JA, Nowell PC, Swerdlow SH, **Kadin ME**, Wasik MA, Salhany KE. Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes. *J Mol Diagn.* 2000;2(1):11-9. Epub 2001/03/29. PubMed PMID: 11272897; PMCID: PMC1906890.
219. Burg G, Dummer R, Haeffner A, Kempf W, **Kadin M.** From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. *Arch Dermatol.* 2001;137(7):949-52. Epub 2001/07/17. PubMed PMID: 11453817.
220. **Kadin ME**, Drews R, Samel A, Gilchrist A, Kocher O. Hodgkin's lymphoma of T-cell type: clonal association with a CD30+ cutaneous lymphoma. *Hum Pathol.* 2001;32(11):1269-72. Epub 2001/12/01. doi: 10.1053/hupa.2001.28963. PubMed PMID: 11727269.
221. **Kadin ME**, Levi E, Kempf W. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. *Ann N Y Acad Sci.* 2001;941:59-68. Epub 2001/10/12. PubMed PMID: 11594583.
222. Kempf W, **Kadin ME**, Kutzner H, Lord CL, Burg G, Letvin NL, Koralnik IJ. Lymphomatoid papulosis and human herpesviruses--A PCR-based evaluation for the presence of human herpesvirus 6, 7 and 8 related herpesviruses. *J Cutan Pathol.* 2001;28(1):29-33. Epub 2001/02/13. PubMed PMID: 11168749.
223. Levi E, Pfeifer WM, **Kadin ME.** CD30-activation-mediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? *Blood.* 2001;98(5):1630-2. Epub 2001/09/08. PubMed PMID: 11547770.
224. Li S, Ross DT, **Kadin ME**, Brown PO, Wasik MA. Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. *Am J Pathol.* 2001;158(4):1231-7. Epub 2001/04/06. doi: 10.1016/S0002-9440(10)64073-4. PubMed PMID: 11290540; PMCID: PMC1891906.
225. Pantanowitz L, Saldinger PF, **Kadin ME.** Pathologic quiz case: Hepatic mass in a patient with renal cell carcinoma. *Arch Pathol Lab Med.* 2001;125(4):577-8. Epub 2001/03/22. doi: 10.1043/0003-9985(2001)125<0577:PQCHMI>2.0.CO;2. PubMed PMID: 11260645.
226. Sposto R, Meadows AT, Chilcote RR, Steinherz PG, Kjeldsberg C, **Kadin ME**, Krailo MD, Termuhlen AM, Morse M, Siegel SE. Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. *Med Pediatr Oncol.* 2001;37(5):432-41. Epub 2001/12/18. PubMed PMID: 11745871.

227. Zhu D, **Kadin ME**, Samoszuk M. Detection of clonal T-cell receptor-gamma gene rearrangement by PCR/temporal temperature gradient gel electrophoresis. *Am J Clin Pathol*. 2001;116(4):527-34. Epub 2001/10/17. doi: 10.1309/8KMV-T6BM-G9PC-EK24. PubMed PMID: 11601137.
228. Pantanowitz L, Saldinger P, **Kadin ME**. Hepatic mass in a patient with renal cell carcinoma. *Arch Pathol and Lab Med*, 125:577-78, 2001.
229. Burg G, Kempf W, Haeffner A, Dobbeling U, Nestle FO, Boni R, **Kadin M**, Dummer R. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. *Recent Results Cancer Res*. 2002;160:271-80. Epub 2002/06/25. PubMed PMID: 1207922
230. Cairo MS, Krailo MD, Morse M, Hutchinson RJ, Harris RE, Kjeldsberg CR, **Kadin ME**, Radel E, Steinherz LJ, Morris E, Finlay JL, Meadows AT. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. *Leukemia*. 2002;16(4):594-600. Epub 2002/04/18. doi: 10.1038/sj.leu.2402402. PubMed PMID: 11960338.
231. Dereure O, Levi E, Vonderheid EC, **Kadin ME**. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. *J Invest Dermatol*. 2002;118(6):949-56. Epub 2002/06/13. doi: 10.1046/j.1523-1747.2002.01794.x. PubMed PMID: 12060388.
232. Horie R, Watanabe T, Ito K, Morisita Y, Watanabe M, Ishida T, Higashihara M, **Kadin M**, Watanabe T. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. *Am J Pathol*. 2002;160(5):1647-54. Epub 2002/05/10. doi: 10.1016/S0002-9440(10)61112-1. PubMed PMID: 12000717; PMCID: PMC1850879.
233. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, **Kadin ME**, Watanabe T. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. *Oncogene*. 2002;21(16):2493-503. Epub 2002/04/24. doi: 10.1038/sj.onc.1205337. PubMed PMID: 11971184.
234. **Kadin ME**. T-cell clonality in pityriasis lichenoides: evidence for a premalignant or reactive immune disorder? *Arch Dermatol*. 2002;138(8):1089-90. Epub 2002/08/08. PubMed PMID: 12164749.
235. Kempf W, Levi E, Kamarashev J, Kutzner H, Pfeifer W, Petrogiannis-Haliotis T, Burg G, **Kadin ME**. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. *J Cutan Pathol*. 2002;29(5):295-300. Epub 2002/07/09. PubMed PMID: 12100631.
236. Lones MA, Perkins SL, Sposto R, Tedeschi N, **Kadin ME**, Kjeldsberg CR, Wilson JF, Zwick DL, Cairo MS. Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. *J Clin Oncol*. 2002;20(9):2293-301. Epub 2002/05/01. doi: 10.1200/JCO.2002.06.017. PubMed PMID: 11981000.
237. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, **Kadin ME**, Pattengale P, Davis PC, Hutchinson RJ, White K, Children's Cancer G. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. *J Clin Oncol*. 2002;20(18):3765-71. Epub 2002/09/14. doi: 10.1200/JCO.2002.12.007. PubMed PMID: 12228196.
238. Willenbrock K, Ichinohasama R, **Kadin ME**, Miura I, Terui T, Meguro K, Fukuhara O, DeCoteau JF, Hansmann ML. T-cell variant of classical Hodgkin's lymphoma with nodal

- and cutaneous manifestations demonstrated by single-cell polymerase chain reaction. *Lab Invest.* 2002;82(9):1103-9. Epub 2002/09/10. PubMed PMID: 12218070.
239. Burg G, Kempf W, Kazakov DV, Dummer R, Frosch PJ, Lange-Ionescu S, Nishikawa T, **Kadin ME**. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. *Br J Dermatol.*
240. Cairo MS, Sposto R, Hoover-Regan M, Meadows AT, Anderson JR, Siegel SE, **Kadin ME**, Kjeldsberg CR, Wilson JF, Perkins SL, Lones MA, Morris E, Finlay JL. Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience. *Am J Hematol.* 2003;72(1):53-63. Epub 2003/01/01. doi: 10.1002/ajh.10262. PubMed PMID: 12508269.
241. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, Siegel SE, Lones MA, Tedeschi-Blok N, **Kadin ME**, Kjeldsberg CR, Wilson JF, Sanger W, Morris E, Krailo MD, Finlay JL. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. *Br J Haematol.* 2003;120(4):660-70. Epub 2003/02/18. PubMed PMID: 12588354.
242. Dereure O, Levi E, Vonderheid EC, **Kadin ME**. Improved sensitivity of T-cell clonality detection in mycosis fungoides by hand microdissection and heteroduplex analysis. *Arch Dermatol.* 2003;139(12):1571-5. Epub 2003/12/17. doi: 10.1001/archderm.139.12.1571. PubMed PMID: 14676072.
243. **Kadin ME**. Genetic and molecular genetic studies in the diagnosis of T-cell malignancies. *Hum Pathol.* 2003;34(4):322-9. Epub 2003/05/07. doi: 10.1053/hupa.2003.94. PubMed PMID: 12733110.
244. **Kadin ME**. Proceedings of the Boston workshop on cytogenetics and molecular genetics of hematologic malignancies, November 8 to 11, 2001: introduction. *Hum Pathol.* 2003;34(4):305. Epub 2003/05/07. doi: 10.1053/hupa.2003.91. PubMed PMID: 12733107.
245. **Kadin ME**, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. *Semin Hematol.* 2003;40(3):244-56. Epub 2003/07/24. PubMed PMID: 12876673.
246. Kempf W, **Kadin ME**, Dvorak AM, Lord CC, Burg G, Letvin NL, Koralknik IJ. Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin. *Carcinogenesis.* 2003;24(2):301-6. Epub 2003/02/14. PubMed PMID: 12584181.
247. Kleinhans M, Tun-Kyi A, Gilliet M, **Kadin ME**, Dummer R, Burg G, Nestle FO. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. *Blood.* 2003;101(4):1487-93. Epub 2002/10/24. doi: 10.1182/blood-2002-02-0475. PubMed PMID: 12393570.
248. Santucci M, Pimpinelli N, Massi D, **Kadin ME**, Meijer CJ, Muller-Hermelink HK, Paulli M, Wechsler J, Willemze R, Audring H, Bernengo MG, Cerroni L, Chimenti S, Chott A, Diaz-Perez JL, Dippel E, Duncan LM, Feller AC, Geerts ML, Hallermann C, Kempf W, Russell-Jones R, Sander C, Berti E, Force ECLT. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. *Cancer.* 2003;97(3):610-27. Epub 2003/01/28. doi: 10.1002/cncr.11107. PubMed PMID: 12548603.
249. Watanabe M, Ogawa Y, Ito K, Higashihara M, **Kadin ME**, Abraham LJ, Watanabe T, Horie R. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. *Am J Pathol.* 2003;163(2):633-41. Epub 2003/07/24. doi: 10.1016/S0002-9440(10)63690-5. PubMed PMID: 12875982; PMCID: PMC1868231.
250. Willers J, Dummer R, Kempf W, Kundig T, Burg G, **Kadin ME**. Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant

- CD30 ligand. *Clin Cancer Res.* 2003;9(7):2744-54. Epub 2003/07/12. PubMed PMID: 12855655.
251. Younes A, **Kadin ME**. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. *J Clin Oncol.* 2003;21(18):3526-34. Epub 2003/09/16. doi: 10.1200/JCO.2003.09.037. PubMed PMID: 12972530.
252. Adams AE, Zwicker J, Curiel C, **Kadin ME**, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. *J Am Acad Dermatol.* 2004;51(4):660-2. Epub 2004/09/25. doi: 10.1016/j.jaad.2004.03.047. PubMed PMID: 15389210.
253. Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, **Kadin ME**, Watanabe T. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. *Cancer Cell.* 2004;5(4):353-64. Epub 2004/04/20. PubMed PMID: 15093542.
254. Lones MA, Sanger WG, Le Beau MM, Heerema NA, Sposto R, Perkins SL, Buckley J, **Kadin ME**, Kjeldsberg CR, Meadows A, Siegel S, Finlay J, Bergeron S, Cairo MS, Children's Cancer Group Study C-E. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. *J Pediatr Hematol Oncol.* 2004;26(3):169-78. Epub 2004/05/06. PubMed PMID: 15125609.
255. Nijsten T, Curiel-Lewandrowski C, **Kadin ME**. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. *Arch Dermatol.* 2004;140(3):306-12. Epub 2004/03/17. doi: 10.1001/archderm.140.3.306. PubMed PMID: 15023774.
256. Rubben A, Kempf W, **Kadin ME**, Zimmermann DR, Burg G. Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma. *Exp Dermatol.* 2004;13(8):472-83. Epub 2004/07/22. doi: 10.1111/j.0906-6705.2004.00176.x. PubMed PMID: 15265011.
257. Schiemann WP, Rotzer D, Pfeifer WM, Levi E, Rai KR, Knaus P, **Kadin ME**. Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptor. *Cancer Detect Prev.* 2004;28(1):57-64. Epub 2004/03/26. doi: 10.1016/j.cdp.2003.11.001. PubMed PMID: 15041079.
258. Franchina M, **Kadin ME**, Abraham LJ. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. *Cancer Epidemiol Biomarkers Prev.* 2005;14(5):1322-5. Epub 2005/05/17. doi: 10.1158/1055-9965.EPI-04-0826. PubMed PMID: 15894695.
259. Greisser J, Doebbeling U, Roos M, Mueller B, Schmid M, Burg G, **Kadin ME**, Kempf W. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. *Exp Dermatol.* 2005;14(5):380-5. Epub 2005/04/28. doi: 10.1111/j.0906-6705.2005.00293.x. PubMed PMID: 15854132.
260. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, **Kadin ME**, Abraham LJ, Watanabe T, Horie R. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. *Cancer Res.* 2005;65(17):7628-34. Epub 2005/09/06. doi: 10.1158/0008-5472.CAN-05-0925. PubMed PMID: 16140928.
261. **Kadin ME**. Pathobiology of CD30+ cutaneous T-cell lymphomas. *J Cutan Pathol.* 2006;33 Suppl 1:10-7. Epub 2006/01/18. doi: 10.1111/j.0303-6987.2006.00507.x. PubMed PMID: 16412208.

262. Lones MA, Heerema NA, Le Beau MM, Perkins SL, **Kadin ME**, Kjeldsberg CR, Sposto R, Meadows A, Siegel S, Buckley J, Finlay J, Abromowitch M, Cairo MS, Sanger WG. Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08. *Cancer Genet Cytogenet.* 2006;171(2):89-96. Epub 2006/11/23. doi: 10.1016/j.cancergencyto.2006.04.019. PubMed PMID: 17116485.
263. Vonderheid EC, **Kadin ME**. Papular mycosis fungoides: a variant of mycosis fungoides or lymphomatoid papulosis? *J Am Acad Dermatol.* 2006;55(1):177-80. Epub 2006/06/20. doi: 10.1016/j.jaad.2006.01.030. PubMed PMID: 16781328.
264. Droc C, Cualing HD, **Kadin ME**. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. *Cancer Control.* 2007;14(2):124-32. Epub 2007/03/28. doi: 10.1177/107327480701400205. PubMed PMID: 17387297.
265. Lones MA, Heerema NA, Le Beau MM, Sposto R, Perkins SL, **Kadin ME**, Kjeldsberg CR, Meadows A, Siegel S, Buckley J, Abromowitch M, Kersey J, Bergeron S, Cairo MS, Sanger WG. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. *Cancer Genet Cytogenet.* 2007;172(1):1-11. Epub 2006/12/19. doi: 10.1016/j.cancergencyto.2006.07.011. PubMed PMID: 17175373.
266. Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, **Kadin ME**, Sternberg DW, Kenner L, Hoefler G. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. *Blood.* 2007;110(9):3374-83. Epub 2007/08/11. doi: 10.1182/blood-2007-02-071258. PubMed PMID: 17690253.
267. Watanabe M, Dewan MZ, Taira M, Shoda M, Honda M, Sata T, Higashihara M, **Kadin ME**, Watanabe T, Yamamoto N, Umezawa K, Horie R. IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. *Lab Invest.* 2007;87(4):372-82. Epub 2007/02/21. doi: 10.1038/labinvest.3700528. PubMed PMID: 17310217.
268. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, Li L, Gooden F, Korenchuk S, Hou XS, Harrington EA, Randolph S, Reilly JF, Ware CM, **Kadin ME**, Frankel SR, Richon VM. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. *Cancer Res.* 2008;68(10):3785-94. Epub 2008/05/17. doi: 10.1158/0008-5472.CAN-07-6091. PubMed PMID: 18483262.
269. **Kadin ME**, Pinkus JL, Pinkus GS, Duran IH, Fuller CE, Onciu M, Kawaguchi H, Morris SW. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. *Am J Surg Pathol.* 2008;32(9):1421-6. Epub 2008/08/02. doi: 10.1097/PAS.0b013e3181648d6d. PubMed PMID: 18670345.
270. Rosenwald IB, Koifman L, Savas L, Chen JJ, Woda BA, **Kadin ME**. Expression of the translation initiation factors eIF-4E and eIF-2 is frequently increased in neoplastic cells of Hodgkin lymphoma. *Hum Pathol.* 2008;39(6):910-6. Epub 2008/02/01. doi: 10.1016/j.humpath.2007.10.021. PubMed PMID: 18234281.
271. Watanabe M, Ogawa Y, Itoh K, Koiwa T, **Kadin ME**, Watanabe T, Okayasu I, Higashihara M, Horie R. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. *Lab Invest.* 2008;88(1):48-57. Epub 2007/10/30. doi: 10.1038/labinvest.3700696. PubMed PMID: 17965727.

272. **Kadin ME.** Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. *Oncology (Williston Park)*. 2009;23(13):1158-64. Epub 2010/01/02. PubMed PMID: 20043465.
273. Kilbridge TM, **Kadin ME.** Teenager with hairy cell leukemia: 30-year follow-up. *J Clin Oncol*. 2009;27(1):155-6. Epub 2008/12/03. doi: 10.1200/JCO.2008.20.3372. PubMed PMID: 19047276.
274. Mathas S, Kreher S, Meaburn KJ, Johrens K, Lamprecht B, Assaf C, Sterry W, **Kadin ME**, Daibata M, Joos S, Hummel M, Stein H, Janz M, Anagnostopoulos I, Schrock E, Misteli T, Dorken B. Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. *Proc Natl Acad Sci U S A*. 2009;106(14):5831-6. Epub 2009/03/27. doi: 10.1073/pnas.0900912106. PubMed PMID: 19321746; PMCID: PMC2667034.
275. Bhargava P, Pantanowitz L, Pinkus GS, Pinkus JL, Paessler ME, Roullet M, Gautam S, Bagg A, **Kadin ME.** Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. *Appl Immunohistochem Mol Morphol*. 2010;18(1):16-23. Epub 2009/06/25. doi: 10.1097/PAI.0b013e3181a307f7. PubMed PMID: 19550297.
276. Braun FK, Hirsch B, Al-Yacoub N, Durkop H, Assaf C, **Kadin ME**, Sterry W, Eberle J. Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. *J Invest Dermatol*. 2010;130(3):826-40. Epub 2009/11/06. doi: 10.1038/jid.2009.299. PubMed PMID: 19890350.
277. Hirsch B, Braun FK, Al-Yacoub N, Assaf C, **Kadin ME**, Sterry W, Eberle J, Durkop H. [cFLIP diminishes CD95-induced apoptosis of CD30-stimulated cutaneous anaplastic large T cell lymphoma (cALCL) cells]. *Pathologe*. 2010;31 Suppl 2:193-8. Epub 2010/09/03. doi: 10.1007/s00292-010-1372-4. PubMed PMID: 20812013.
278. **Kadin ME.** Macrophages in Hodgkin's lymphoma. *N Engl J Med*. 2010;362(22):2135-6; author reply 6. Epub 2010/06/09. PubMed PMID: 20527059.
279. **Kadin ME**, Vonderheid EC. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL. *Nat Rev Clin Oncol*. 2010;7(8):430-2. Epub 2010/07/30. doi: 10.1038/nrclinonc.2010.105. PubMed PMID: 20668480.
280. Rathore B, **Kadin ME.** Hodgkin's lymphoma therapy: past, present, and future. *Expert Opin Pharmacother*. 2010;11(17):2891-906. Epub 2010/11/06. doi: 10.1517/14656566.2010.515979. PubMed PMID: 21050034; PMCID: PMC2978071.
281. Turner JJ, Morton LM, Linet MS, Clarke CA, **Kadin ME**, Vajdic CM, Monnereau A, Maynadie M, Chiu BC, Marcos-Gragera R, Costantini AS, Cerhan JR, Weisenburger DD. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. *Blood*. 2010;116(20):e90-8. Epub 2010/08/12. doi: 10.1182/blood-2010-06-289561. PubMed PMID: 20699439; PMCID: PMC2993636.
282. Vonderheid EC, **Kadin ME**, Gocke CD. Lymphomatoid papulosis followed by pityriasis lichenoides: a common pathogenesis? *Am J Dermatopathol*. 2011;33(8):835-40. Epub 2011/11/02. doi: 10.1097/DAD.0b013e3181f4d8c3. PubMed PMID: 22042257.
283. Watanabe M, Nakano K, Togano T, Nakashima M, Higashihara M, **Kadin ME**, Watanabe T, Horie R. Targeted repression of overexpressed CD30 downregulates NF-kappaB and ERK1/2 pathway in Hodgkin lymphoma cell lines. *Oncol Res*. 2011;19(10-11):463-9. Epub 2011/01/01. PubMed PMID: 22715589.
284. **Kadin ME**, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early

- mycosis fungoides. *J Invest Dermatol.* 2012;132(3 Pt 1):703-10. Epub 2011/11/11. doi: 10.1038/jid.2011.351. PubMed PMID: 22071475; PMCID: PMC3278552.
285. Vasmatazis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, Thompson EA, **Kadin ME**, Milosevic D, Porcher JC, Asmann YW, Smith DI, Kovtun IV, Ansell SM, Dogan A, Feldman AL. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. *Blood.* 2012;120(11):2280-9. Epub 2012/08/03. doi: 10.1182/blood-2012-03-419937. PubMed PMID: 22855598; PMCID: PMC5070713.
286. Watanabe M, Itoh K, Togano T, **Kadin ME**, Watanabe T, Higashihara M, Horie R. Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma. *Am J Pathol.* 2012;180(2):831-8. Epub 2011/11/24. doi: 10.1016/j.ajpath.2011.10.007. PubMed PMID: 22107829; PMCID: PMC4429177.
287. Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, Sposto R, **Kadin ME**, Hutchinson RJ, Nachman J. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. *J Clin Oncol.* 2012;30(26):3174-80. Epub 2012/06/01. doi: 10.1200/JCO.2011.41.1819. PubMed PMID: 22649136; PMCID: PMC3434976.
288. Csikesz CR, Knudson RA, Greipp PT, Feldman AL, **Kadin M**. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders with biallelic rearrangements of DUSP22. *J Invest Dermatol.* 2013;133(6):1680-2. Epub 2013/01/23. doi: 10.1038/jid.2013.22. PubMed PMID: 23337887.
289. Ehrentraut S, Nagel S, Scherr ME, Schneider B, Quentmeier H, Geffers R, Kaufmann M, Meyer C, Prochorec-Sobieszek M, Ketterling RP, Knudson RA, Feldman AL, **Kadin ME**, Drexler HG, MacLeod RA. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. *PLoS One.* 2013;8(1):e53767. Epub 2013/02/02. doi: 10.1371/journal.pone.0053767. PubMed PMID: 23372669; PMCID: PMC3553112.
290. Karai LJ, **Kadin ME**, Hsi ED, Sluzevich JC, Ketterling RP, Knudson RA, Feldman AL. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. *Am J Surg Pathol.* 2013;37(8):1173-81. Epub 2013/05/08. doi: 10.1097/PAS.0b013e318282d01e. PubMed PMID: 23648461.
291. Aschebrook-Kilfoy B, Cocco P, La Vecchia C, Chang ET, Vajdic CM, **Kadin ME**, Spinelli JJ, Morton LM, Kane EV, Sampson JN, Kasten C, Feldman AL, Wang SS, Zhang Y. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sezary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr.* 2014;2014(48):98-105. Epub 2014/09/01. doi: 10.1093/jncimonographs/lgu008. PubMed PMID: 25174030; PMCID: PMC4155463.
292. **Kadin ME**, Hughey LC, Wood GS. Large-cell transformation of mycosis fungoides--differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. *J Am Acad Dermatol.* 2014;70(2):374-6. Epub 2014/01/21. doi: 10.1016/j.jaad.2013.09.007. PubMed PMID: 24438952.
293. Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, Smedby KE, de Sanjose S, Monnereau A, Benavente Y, Bracci PM, Chiu BC, Skibola CF, Zhang Y, Mbulaiteye SM, Spriggs M, Robinson D, Norman AD, Kane EV, Spinelli JJ, Kelly JL, La Vecchia C, Dal Maso L, Maynadie M, **Kadin ME**, Cocco P, Costantini AS, Clarke CA, Roman E, Miligi L, Colt JS, Berndt SI, Mannetje A, de Roos AJ, Krickler A, Nieters A, Franceschi S, Melbye M, Boffetta P, Clavel J, Linet MS, Weisenburger DD, Slager SL. Rationale and design of the International Lymphoma Epidemiology Consortium

- (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr.* 2014;2014(48):1-14. Epub 2014/09/01. doi: 10.1093/jncimonographs/igu005. PubMed PMID: 25174022; PMCID: PMC4155460.
294. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjose S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadie M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, **Kadin ME**, Paltiel O, Weisenburger DD, Linet MS, Sampson JN. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr.* 2014;2014(48):130-44. Epub 2014/09/01. doi: 10.1093/jncimonographs/igu013. PubMed PMID: 25174034; PMCID: PMC4155467.
295. Vonderheid EC, Pavlov I, Delgado JC, Martins TB, Telang GH, Hess AD, **Kadin ME**. Prognostic factors and risk stratification in early mycosis fungoides. *Leuk Lymphoma.* 2014;55(1):44-50. Epub 2013/04/04. doi: 10.3109/10428194.2013.790541. PubMed PMID: 23547839.
296. Wang SS, Flowers CR, **Kadin ME**, Chang ET, Hughes AM, Ansell SM, Feldman AL, Lightfoot T, Boffetta P, Melbye M, Lan Q, Sampson JN, Morton LM, Zhang Y, Weisenburger DD. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr.* 2014;2014(48):66-75. Epub 2014/09/01. doi: 10.1093/jncimonographs/igu012. PubMed PMID: 25174027; PMCID: PMC4155466.
297. Wang Y, Gu X, Zhang G, Wang L, Wang T, Zhao Y, Zhang X, Zhou Y, **Kadin M**, Tu P. SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. *Blood.* 2014;123(22):3452-61. Epub 2014/04/22. doi: 10.1182/blood-2013-10-534693. PubMed PMID: 24747435.
298. Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, Wittig BM, Warszawska K, Kurek A, Erdmann-Keding M, Kunz S, Asadullah K, **Kadin ME**, Volk HD, Sterry W, Wolk K, Sabat R. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. *J Invest Dermatol.* 2014;134(11):2757-67. Epub 2014/07/22. doi: 10.1038/jid.2014.308. PubMed PMID: 25046339.
299. Wolk K, Mitsui H, Witte K, Gellrich S, Gulati N, Humme D, Witte E, Gonsior M, Beyer M, **Kadin ME**, Volk HD, Krueger JG, Sterry W, Sabat R. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. *Clin Cancer Res.* 2014;20(21):5507-16. Epub 2014/09/13. doi: 10.1158/1078-0432.CCR-14-0707. PubMed PMID: 25212608.
300. Guitart J, Martinez-Escala ME, Deonizio JM, Gerami P, **Kadin ME**. CD30(+) cutaneous lymphoproliferative disorders with pseudocarcinomatous hyperplasia are associated with a T-helper-17 cytokine profile and infiltrating granulocytes. *J Am Acad Dermatol.* 2015;72(3):508-15. Epub 2015/01/15. doi: 10.1016/j.jaad.2014.11.021. PubMed PMID: 25582534.

301. **Kadin ME.** CD30-rich transformed mycosis fungoides or anaplastic large cell lymphoma? How to get it right. *Br J Dermatol.* 2015;172(6):1478-9. Epub 2015/06/04. doi: 10.1111/bjd.13808. PubMed PMID: 26036155.
302. Martinez-Escala ME, Sidiropoulos M, Deonizio J, Gerami P, **Kadin ME**, Guitart J. gammadelta T-cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous gammadelta T-cell lymphomas. *Br J Dermatol.* 2015;172(2):372-9. Epub 2014/08/22. doi: 10.1111/bjd.13364. PubMed PMID: 25143223.
303. Toda T, Watanabe M, Kawato J, **Kadin ME**, Higashihara M, Kunisada T, Umezawa K, Horie R. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines. *Br J Haematol.* 2015;170(6):837-46. Epub 2015/06/25. doi: 10.1111/bjh.13508. PubMed PMID: 26105086.
304. Andrique L, Poglio S, Prochazkova-Carlotti M, **Kadin ME**, Giese A, Idrissi Y, Beylout-Barry M, Merlio JP, Chevret E. Intrahepatic Xenograft of cutaneous T-cell lymphoma cell lines: a useful model for rapid biological and therapeutic evaluation. *Am J Pathol.* 2016;186(7):1775-85. Epub 2016/05/18. doi: 10.1016/j.ajpath.2016.03.012. PubMed PMID: 27181405.
305. Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, **Kadin ME**, Bensussan A, Bagot M, Michel L. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. *Br J Dermatol.* 2016;175(2):325-33. Epub 2016/04/03. doi: 10.1111/bjd.14626. PubMed PMID: 27037558.
306. Ehrentraut S, Schneider B, Nagel S, Pommerenke C, Quentmeier H, Geffers R, Feist M, Kaufmann M, Meyer C, **Kadin ME**, Drexler HG, MacLeod RA. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma. *Oncotarget.* 2016;7(23):34201-16. Epub 2016/05/05. doi: 10.18632/oncotarget.9077. PubMed PMID: 27144517; PMCID: PMC5085149
307. Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, **Kadin ME**, Brody G, Clemens M, Cheah CY, Lade S, Joshi PA, Prince HM, Deva AK. Bacterial Biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma. *Plast Reconstr Surg.* 2016;137(6):1659-69. Epub 2016/02/19. doi: 10.1097/PRS.0000000000002010. PubMed PMID: 26890506.
308. **Kadin ME**, Deva A, Xu H, Morgan J, Khare P, MacLeod RA, Van Natta BW, Adams WP, Jr., Brody GS, Epstein AL. Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J.* 2016;36(7):773-81. Epub 2016/03/17. doi: 10.1093/asj/sjw023. PubMed PMID: 26979456.
309. Vonderheid EC, **Kadin ME**, Telang GH. Commentary about papular mycosis fungoides, lymphomatoid papulosis and lymphomatoid pityriasis lichenoides: more similarities than differences. *J Cutan Pathol.* 2016;43(4):303-12. Epub 2015/11/15. doi: 10.1111/cup.12653. PubMed PMID: 26566599.
310. Vonderheid EC, Hamilton RH, **Kadin ME**. Investigation of Atopy in Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders. *Clinical Dermatology Open Access Journal*, 2: 108, 2016
311. Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, **Kadin ME**, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. *Proc Natl Acad Sci U S A.* 2017;114(15):3975-80. Epub 2017/03/31. doi: 10.1073/pnas.1700682114. PubMed PMID: 28356514; PMCID: PMC5393253.

312. Fan P, Nong L, Sun J, Liu X, **Kadin ME**, Li T, Tu P, Wang Y. Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema. *J Cutan Pathol*. 2017. Epub 2017/03/25. doi: 10.1111/cup.12933. PubMed PMID: 28337783.
313. **Kadin ME**, Glicksman CA. Commentary on: Breast implant-associated anaplastic large-cell lymphoma in a transgender woman. *Aesthet Surg J*. 2017;37(8):NP88-NP9. Epub 2017/10/19. doi: 10.1093/asj/sjx105. PubMed PMID: 29036946.
314. **Kadin ME**, Morgan J, Xu H, Glicksman CA. CD30+ T Cells in late seroma may not be diagnostic of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J*. 2017;37(7):771-5. Epub 2017/04/13. doi: 10.1093/asj/sjw286. PubMed PMID: 28402493.
315. Maliniemi P, Laukkanen K, Vakeva L, Dettmer K, Lipsanen T, Jeskanen L, Bessede A, Oefner PJ, **Kadin ME**, Ranki A. Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas. *Oncoimmunology*. 2017;6(3):e1273310. Epub 2017/04/14. doi: 10.1080/2162402X.2016.1273310. PubMed PMID: 28405495; PMCID: PMC5384345.
316. Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, **Kadin ME**, Waldmann TA, Perera PY. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. *Am J Hematol*. 2017;92(9):892-901. Epub 2017/05/26. doi: 10.1002/ajh.24794. PubMed PMID: 28543380; PMCID: PMC5546946.
317. Wang X, Boddicker RL, Dasari S, Sidhu JS, **Kadin ME**, Macon WR, Ansell SM, Ketterling RP, Rech KL, Feldman AL. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. *Hum Pathol*. 2017;64:19-27. Epub 2017/02/06. doi: 10.1016/j.humpath.2017.01.003. PubMed PMID: 28153507; PMCID: PMC5518937.
318. Wang X, Dasari S, Nowakowski GS, Lazaridis KN, Wieben ED, **Kadin ME**, Feldman AL, Boddicker RL. Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. *Oncotarget*. 2017;8(16):26245-55. Epub 2017/04/17. doi: 10.18632/oncotarget.15441. PubMed PMID: 28412739; PMCID: PMC5432253.
319. Watanabe M, Nakano K, **Kadin ME**, Higashihara M, Watanabe T, Horie R. CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells. *Am J Pathol*. 2017;187(1):163-75. Epub 2016/11/22. doi: 10.1016/j.ajpath.2016.09.007. PubMed PMID: 27870927.
320. **Kadin ME**, Morgan J, Xu H, Epstein AL, Sieber D, Hubbard BA, Adams WP, Jr., Bacchi CE, Goes JCS, Clemens MW, Medeiros LJ, Miranda RN. IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. *Hum Pathol*. 2018;78:54-62. Epub 2018/04/25. doi: 10.1016/j.humpath.2018.04.007. PubMed PMID: 29689246.
321. Sun J, Yi S, Qiu L, Fu W, Wang A, Liu F, Wang L, Wang T, Chen H, Wang L, **Kadin ME**, Tu P, Wang Y. SATB1 Defines a subtype of cutaneous CD30(+) lymphoproliferative disorders associated with a T-Helper 17 cytokine profile. *J Invest Dermatol*. 2018;138(8):1795-804. Epub 2018/03/07. doi: 10.1016/j.jid.2018.02.028. PubMed PMID: 29510190.
322. Yi S, Sun J, Qiu L, Fu W, Wang A, Liu X, Yang Y, **Kadin ME**, Tu P, Wang Y. Dual Role of EZH2 in cutaneous anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment. *J Invest Dermatol*. 2018;138(5):1126-36. Epub 2017/12/19. doi: 10.1016/j.jid.2017.10.036. PubMed PMID: 29248547.
323. Hanson SE, Hassid VJ, Branch-Brooks C, Liu J, **Kadin ME**, Miranda R, Butler CE, Clemens MW. Validation of a CD30 enzyme-linked immunosorbant assay for the rapid

- detection of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J*. 2019. Epub 2019/02/23. doi: 10.1093/asj/sjy327. PubMed PMID: 30789639.
324. **Kadin ME**. What cytokines can tell us about the pathogenesis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). *Aesthet Surg J*. 2019;39(Supplement_1):S28-S35. Epub 2019/02/05. doi: 10.1093/asj/sjy250. PubMed PMID: 30715174.
325. Zhang JP, Song Z, Wang HB, Lang L, Yang YZ, Xiao W, Webster DE, Wei W, Barta S K, **Kadin ME**, Staudt LM, Nakagawa M, Yang Y. A novel model of controlling PD-L1 expression in ALK+ Anaplastic Large Cell Lymphoma revealed by CRISPR screening. *Blood*, 2019 pii: blood.2019001043. doi: 10.1182/blood.2019001043. [Epub ahead of print]
326. Luchtel RA, Zimmermann MT, Hu G, Dasari S, Jiang M, Oishi N, Jacobs HK, Zeng Y, Hundal T, Rech KL, Ketterling RP, Lee JH, Eckloff BW, Yan H, Gaonkar KS, Tian S, Ye Z, **Kadin ME**, Sidhu J, Jiang L, Voss J, Link BK, Syrbu SI, Facchetti F, Bennani NN, Slager SL, Ordog T, Kocher JP, Cerhan JR, Ansell S, Feldman AL. Recurrent *MSC^{E116K}* mutations in ALK-negative anaplastic large cell lymphoma. *Blood*. 2019 May 17. pii: blood.2019000626. doi: 10.1182/blood.2019000626. [Epub ahead of print]
327. Vonderheid EC, Hamilton RH, **Kadin ME**. Prevalence of atopy and Staphylococcal superantigen specific IgE antibodies and total serum IgE in primary cutaneous T and B cell lymphoma. *The Journal of Dermatology*, 2019, 46 (12) ;1170-1178. Doi.10.1111/1346-8138.15059. PMID:31587349..
328. Vonderheid EC, Kantor GR, Telang GH, Bujanouskas P, **Kadin ME**. A histo-immunopathologic and prognostic study of erythrodermic cutaneous T cell lymphoma. *Journal of Cutaneous Pathology*, 2019, 43: 913-924, doi:10. 1111/cup.13563
329. **Kadin ME**, Adams WP, Inghirami G, DiNapoli A. Does Breast Implant Associated ALCL begin as a lymphoproliferative disorder? *Plastic and Reconstructive Surgery*, 2020, Jan 145(1) 30e-38e. doi 10.1097/PRS.00000000000006390. PMID:31577659.
330. Turner SD Inghirami G, Miranda RN, **Kadin ME**. Cell of origin and immunological events in the pathogenesis of breast implant associated anaplastic large cell lymphoma. *American Journal of Pathology*, 2020, 190 (1), 2-10. doi:1016/ajpath.2019.09.0005. PMID 31610171.
331. **Kadin ME**, Morgan J, Kouttab N, Xu H, Adams WP, Glicksman C, McGuire P, Sieber D, Epstein AL, Miranda RN, Clemens MW. Comparative analysis of cytokines of tumor cells and malignant and benign effusions around breast implants. *Aesthetic Surgery Journal*, 2019 Sep 7, pii sjz243. doi 10.1093/asj/sjz243. PMID31589747
332. Mukhtar R, Holland M, Sieber D, Wen KW, Hope S, **Kadin ME**, Bean GS. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications. *Plast Reconstr Surg Glob Open*. 2019 Apr; 7(4): e2188
333. Gao Y, Liu F, Sun J, Wen Y, Tu P, **Kadin ME**, Wang Y. Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T Cell Lymphoma. *Journal of Investigative Dermatology*, 2020 Aug 07. PMID: 32771472.
334. Wen J, Sun J, Yi S, Morgan, Kouttab N, Wang Y, **Kadin ME**. IL-13 signaling in cutaneous CD30+ lymphoproliferative disorders. *Journal Investigative Dermatology*, 2020, 10. PMID: 33049271.
335. Arianna Di Napoli; Daniele Greco; Giorgia Scafetta; Francesca Ascenzi; Alessandro Gulino; Luigi Aurisicchio; Fabio Di Pompeo Santanelli; Adriana Bonifacino; Enrico Giarnieri; John Morgan; Rita Mancini; **Marshall E Kadin**. IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant associated anaplastic large cell lymphoma from all types of benign late seromas *Cancer Immunology and Immunotherapy*, 2021; 70(5): 1379–1392. Nov 04. PMID: 33146828.

336. **Kadin ME**, Morgan J, Xu H, Glicksman C, Adams WP, McGuire P, Clemens MW, Thakur A, Lum L. Granzyme B is a biomarker for suspicion of malignant seromas around breast implants. *Aesthetic Surgery Journal*, 2020 Nov 09. PMID: 33165542.
337. Wang H, Wei W, Zhang JP, Zh Song JH, Li2Y, Xiao W. Lii Y, Zeng MS, Petrus MN, Thomas CJ, **Kadin ME**, Nakagawa M, Waldmann, TA, Yang Y. A novel model of alternative NF- κ B pathway activation in Anaplastic Large Cell Lymphoma, *Leukemia*, 2020 Nov 12. PMID: 33184494.
338. Vonderheid EC, Hamilton R, **Kadin ME**. Mycosis fungoides and its relationship to atopy, serum total IgE and eosinophil counts. *Clinical Lymphoma, Myeloma and Leukemia*, 2020 Nov 12:S2152-2650(20)30631-5. doi: 10.1016/j.clml.2020.11.007.
339. Deva A, Prince M, **Kadin ME**, Magnussun M, Miranda R, Inghirami GG, Adams WP. Etiology of Breast Implant–Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. *Cancers*, 12(12)3861 DOI: [10.3390/cancers12123861](https://doi.org/10.3390/cancers12123861)
340. Stonesifer C, Joseph Grimes j, Garcia-Saleem T, Niedt G, **Kadin ME**, Geskin L. *Stenotrophomonas Maltophilia*-Associated Primary Cutaneous Anaplastic Large Cell Lymphoma, *JAAD case reports*. <https://doi.org/10.1016/j.jdcr.2021.08.006>
341. Merlio JP, **Kadin ME**. Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas. *Cancers*, 2021, doi: 10.3390/cancers13174256
342. Mempin M, Hu H, Vickery K, **Kadin ME**, Prince HM, Hu H, Joshi H, Mufsid JC, Xu H, Kouttab N, Adams WP, Deva AK. Gram-negative lipopolysaccharide (LPS) promotes neoplastic proliferation in breast implant associated anaplastic large-cell lymphoma. *Cancers* **2021**, 13(21), 5298; <https://doi.org/10.3390/cancers13215298>
343. Du J, Yu, Zhao T, Wang H, Zhang LX, Qin G, Zhuang S, Kadin M, Chin YE, Liu PY, Zhao T. The essential role of PRAK in preserving cardiac function and insulin resistance in high fat diet-induced diabetes. *Int J Mol Sciences*, 2021, 22 (15), 7995
344. Herrera A, Cheng A, Mimitou EP, Seffens A, George D, Bar-Natan, M, Heguy A, Ruggles KV, Sher JU, Hymes K, Latkowski JA, Odum N, **Kadin ME**, Ouyan Z Geskin LJ, Smibert P, Buus TB, Koralov SB. Multimodal single cell analysis of cutaneous T cell lymphoma reveals subclonal tissue-dependent signatures, *Blood*. 2021 Oct 21;138(16):1456-1464. doi: 10.1182/blood.2020009346.PMID: 34232982
345. Song Z, Wu W, Wei W, Xiao W, Lei M, Cai K, Zhang JP, Wang H, Huang DW, Nakagawa M, **Kadin ME**, Waldmann TA, Staudt L, Yang Y. Analysis and Therapeutic Targeting of the IL-1R Pathway in Anaplastic Large Cell Lymphoma, *Nature Cancer*, under review.
346. Impact of Capsulectomy Type on Post-Explantation. Systemic Symptom Improvement: Findings from the Aesthetic Surgery Systemic Symptoms in Women-Biospecimen Analysis Study. Glicksman C, **Kadin ME**, Sung J, Maguire P. *Aesthetic Surgery Journal*, under review.

NON-PEER REVIEWED PUBLICATIONS

1. **Kadin ME**, Gold SB, Garratty EM, Stites DP. Immunological membrane markers of Hodgkin's cells. In Neth R, Gallo RC, Mannweler K, Maloney WC, Lehman F (eds): *Modern Trends in Human Leukemia II*, Verlag, Munich, 1976.
2. Bowles C, Bull B, Mc Cormick , Lucas D, **Kadin ME**, Graw R, Jr. Combined modality therapy for spontaneous canine lymphoma, in: Okunewich JP and Meredith RF (eds): *Graft Versus Leukemia in Man and Animal Models*, CRC Press, Cleveland OH, 1979.

3. **Kadin ME**, Berard CW, Nanba K, Wakasa H. Lymphoproliferative disease in Japan and Western countries: Proceedings of the United States-Japan Seminar, September 6 and 7, 1982 in Seattle WA. *Human Pathol* 1983,14:745-772.
4. **Kadin ME**. T cell malignancies: Can pathology and clinical features be predicted from tumor cell phenotype? In: *Advances in Human Lymphoma*. M.D. Anderson Clinical Conference on Cancer, Vol. 27, eds. RJ Ford, LM Fuller, FB Hagemester. Raven Press, pp. 249-262, 1984.
5. **Kadin ME**. Cutaneous Ki-1 lymphomas: Pathology, immunology and clinical characteristics, *Int Symposium Princess Takamatsu Cancer Res Fund*, 1987,18:187-95.
6. **Kadin ME**. The spectrum of Ki-1+ cutaneous lymphomas. In van Vloten WA, Willemze R, Lange Vejlsgaard G, Thomsen K (eds): *Cutaneous Lymphoma. Current Problems in Dermatology*, Basel, Karger, 1990, vol 19, pp 132-43.
7. **Kadin ME**. Immunohistochemistry of lymphomatoid papulosis. In Muller SA, *Proceedings of the First International Symposium on Parapsoriasis*, Rochester MN. Sept 7 -8, 1989, Mayo Foundation, 1990, pp 56-60.
8. **Kadin ME**. Lymphomatoid papulosis and Ki-1+ large cell lymphomas of the skin: pathology, immunology, natural history and relevance to Hodgkin's disease. In: Hanaoka M, **Kadin ME**, Nanba K, Watanabe S (eds) *International Colloquium on Lymphoid Malignancy. Immunocytology and Cytogenetics*. Field and Woods. Philadelphia PA, 1990, pp. 189-195.
9. **Kadin ME**. Characteristic immunological profile of large atypical cells in lymphomatoid papulosis- possible implications for histogenesis and relationship to other diseases. *Archives of Dermatology*, 1986,122:1388-90.
10. Abrams JT, Lessin S, Ju W, Vonderheid EC, Rook A, Nowell P, **Kadin ME**, De Freitas : Analysis of T cells and long-term T-cell lines from patients with Sezary syndrome. In *Human Retrovirology; HTLV*. Edited by William A. Blattner, Raven Press, New York 1990, pp 147-61.
11. **Kadin ME**. Pathology and Origin of Hodgkin's disease, in Benz EJ, Cohen HJ, Furie B, Hoffman R, Shattil SJ (eds): *Hematology: basic principles and practice*. Churchill-Livingstone, New York, 1991, Chapter 71, pp 912-920.
12. **Kadin ME**. Ki-1 positive anaplastic large cell lymphoma-- a clinicopathologic entity ? *Journal of Clinical Oncology*, 9:533-36,1991.
13. **Kadin ME**. Unexpected finding- Biologic truth or technical artifact? *Human Pathol* 1991, 22:941-43.
14. **Kadin ME**. Lymphomatoid papulosis, Ki-1+ cutaneous lymphoma and primary cutaneous Hodgkin's disease. *Seminars in Dermatology*, 1991, 10:164-71
15. **Kadin ME**. Lymphomatoid papulosis-- A model for tumor progression in Ki-1+ cutaneous lymphomas, in *Lymphomas of the Skin*, Vol X, edit. M Yamada, H Nakajima, Cutaneous Lymphoma Study Group, Hamamatsu Japan. 1991, pp 13-22.
16. **Kadin ME**. Marti R. Linfomas Ki-1+. Aspectos dermatologicos. *Piel* 1993, 8:367-369.
17. **Kadin ME**. Ki-1+ (anaplastic) large cell lymphoma: Maturation of a clinicopathologic entity with prospects of effective therapy. *Journal of Clinical Oncology*, 12:884-888,1994.
18. Vonderheid EC, Kantor GR, Pequignot EC, Lessin SR, Nowell PC, Elfenbein IB, Kerrigan K, **Kadin ME**: Analysis of clinical, histopathologic, and immunopathologic parameters in erythrodermic variants of cutaneous T-cell lymphoma with implications for staging. Editors, WC Lambert, W van Vloten, *NATO Advanced Science Institute Series. Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin*, Plenum Press, 1994, pp. 275-290.

19. **Kadin ME**, Davis TH, Balk SP, Newcom SR, Cheifitz S, Massague J. Mechanism for tumor progression in lymphomatoid papulosis: Hypothesis based on studies of tumor cell lines clonally derived from lymphomatoid papulosis. Editors, WC Lambert, W van Vloten, NATO Advanced Science Institute Series. Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin, Plenum Press, 1994, pp 425-33.
20. De Coteau JF, **Kadin ME**. New insights into peripheral T cell lymphomas. *Current Opinion in Oncology*, 1995, 7:408-414.
21. Agnarsson BA, **Kadin ME**. Peripheral T cell lymphomas in children. *Seminars in Diagnostic Pathology*. 1995, 12:314-24.
22. Rudiger T, Jaffe ES, Delsol G, deWolf-Peeters C, Gascoyne R, Georgii A, Harris NL, **Kadin ME**, MacLennan KA, Poppema S, Stein H, Weiss LM, Muller-Hermelink HK. Workshop report on Hodgkin's lymphoma and related diseases (grey zone lymphoma) *Ann Oncol*. 9, suppl 5, 531-538, 1998.
23. **Kadin ME**, Morris SW. The t(2;5) in human lymphomas. *Leukemia and Lymphoma*, 1998; 29:249-56.
24. Kinney MC, **Kadin ME**. The pathologic and clinical spectrum of anaplastic large cell lymphoma (ALCL) and correlation with ALK gene dysregulation. *Pathology Patterns*, 111 (suppl 1) S56-S67, 1999.
25. **Kadin ME**. Primary CD30+ cutaneous lymphomas (including lymphomatoid papulosis), Chapter 38 in *Human Lymphoma: Clinical Implications of the REAL Classification*. Editors D.Y. Mason and Nancy L. Harris, Springer-Verlag, 1999.
26. **Kadin ME**, Levi E, Kempf. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by TGF-beta and CD30 ligand. *N.Y. Acad. Sci*, 941:59-68, 2001.
27. Drews R, Samel A, **Kadin ME**. Lymphomatoid papulosis and anaplastic large cell lymphoma of the skin. In *Seminars in Cutaneous Medicine and Surgery*. Editors, KA Arndt, PE LeBoit, JK Robinson, BU Wintroub, 19:109-117, 2000.
28. **Kadin ME**. Cutaneous gamma-delta T-cell lymphomas- Why and how will they be recognized? Editorial, *Archives of Dermatology*, 136: 52-54, 2000.
29. Burg G, Dummer R, Kempf W, **Kadin ME**. From inflammation to neoplasia. *Mycosis fungoides* evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. Editorial, *Archives of Dermatology*, 137:949952, 2001.
30. **Kadin ME**. T-cell clonality in Pityriasis Lichenoides- evidence for a premalignant or reactive immune disorder? Editorial, *Archives of Dermatology*, 138:1089-90, 2002.
31. Younes A, **Kadin ME**. Tumor necrosis factor family of ligands and receptors: Clinical implications and emerging therapeutic applications in benign and malignant hematologic disorders. *Journal of Clinical Oncology*, 21:3526-34, 2003.
32. **Kadin ME**. Genetic and molecular genetic studies in the diagnosis of T cell malignancies. *Human Pathology*, 34:322-29, 2003.
33. **Kadin ME**. Extracutaneous origin of lymphomatoid papulosis. *Blood*, 102:3468, 2003.
34. **Kadin ME**, Carpenter C. Hidden identity of Hodgkin/Reed-Sternberg cells, *Blood*, 103:7, 2004.
35. **Kadin ME**. Latest lymphoma classification is skin deep, *Blood*, 2005, 105:3759
36. Droc C, Cualing H, **Kadin ME**. Need for improved molecular/genetic classification of CD30+ lymphoproliferative disorders involving the skin. *Cancer Control*, 14:1-9, 2007.
37. **Kadin ME**. Current management of primary cutaneous CD30+ T cell lymphoproliferative disorders. *Oncology* 2009, 23:1158-64.

38. **Kadin ME.** Vonderheid EC. Invited commentary on Phase III placebo-controlled trial of denileukin for patients with cutaneous T-cell lymphoma. *Nature Reviews in Clinical Oncology*, 2010, 7:430-32.
39. **Kadin ME.** Glicksman CA. Invited commentary on: Breast Implant-Associated Anaplastic Large-Cell Lymphoma in a Transgender Woman, *Aesthetic Surgery Journal*, 2017.

BOOKS AND BOOK CHAPTERS

1. **Kadin ME.** Uncommon lymphomas, In: Newcom SR, **Kadin ME** (eds) *Diagnosis and Management of Hematologic Malignancies*, Addison-Wesley, Menlo Park CA, 1981.
2. Newcom SR, **Kadin ME.** Hodgkin's Disease, In: Newcom SR, **Kadin ME** (eds) *Diagnosis and Management of Hematologic Malignancies*, Addison-Wesley, Menlo Park CA, 1981.
3. **Kadin ME.** The Reed-Sternberg cell: biological and clinical significance. In: Bennett JM, Nijhoff M (eds.) *Lymphomas Including Hodgkin's disease II*, The Hague/Boston/London, pp. 55-90,1983.
4. Magrath I, **Kadin ME.** Large cell lymphomas in children. In: Magrath Ian (edit.) *Non-Hodgkin's Lymphomas*, Edward Arnold Publishers, Ltd. London England, 1990, pp 279-91.
5. **Kadin ME.** Hodgkin's disease: Immunobiology and pathogenesis. In Knowles DM (edit) *Neoplastic Hematology*, Williams and Wilkins, 1992, pp.535-554.
6. Reich PR, **Kadin ME,** Weller PF. Leukocytes in Hematology. *Pathophysiologic Basis for Clinical Practice*, 3rd edition. Little Brown and Company, Boston, edited by Stephen H Robinson and Paul R Reich, 1993, pp. 229-263.
7. Loughran TP Jr., **Kadin ME.** Large granular lymphocyte leukemia. In Williams Hematology, 5th Edition, edited by Ernest Beutler, MD, Marshall Lichtman, MD, Barry S Coller, MD, and Thomas J Kipps, MD, Ph D, Mc Graw-Hill, 1995, pp 1047-1049.
8. **Kadin, ME.** Lymphomatoid papulosis. In: Arndt KA, Le Boit PE, Robinson JK, Wintroub BU, editors. *Cutaneous Medicine and Surgery: An Integrated Program in Dermatology*. Volume 2. WB Saunders Co. Philadelphia, 1996, pp. 1631-68.
9. Agnarsson BA, **Kadin ME.** Ki-1 (CD30) positive large cell lymphoma. In *Pathology of Lymph Nodes*, edited by Lawrence M. Weiss, MD, Churchill Livingstone, New York, 1996, pp 381-98.
10. **Kadin ME,** Kinney MC: Pathogenesis of Ki-1+ Lymphomas. *The Non-Hodgkin's Lymphomas*, edited by Ian Macgrath, Second Edition, Edward Arnold, London,1997, pp.443-58.
11. **Kadin ME.** Anaplastic large cell lymphoma and its variants. *Cancer Surveys* volume 30, Lymphoma. Guest Editor, AC Wotherspoon. Series Editor, J Tooze. 1997 Imperial Cancer Research Fund. Cold Spring Harbor Press, pp.77-86.
12. **Kadin ME,** Leibowitz D. Cytokines and Cytokine Receptors in Hodgkin's disease, in *Hodgkin's Disease*, edited by P Mauch, J Armitage, V Diehl, R Hoppe, L Weiss. Lippincott-Williams and Wilkins, Philadelphia PA, 1999, pp 139-57.
13. **Kadin ME.** Hodgkin's Disease: Cell of Origin, Immunobiology and Pathogenesis, in *Neoplastic Hematopathology*, Editor, Daniel M. Knowles, Lippincott, Williams and Wilkins, Baltimore MD, 2nd Edition, 2000, pp. 667-690.
14. Loughran TP, Jr., **Kadin ME.** Large Granular Lymphocyte Leukemia. In Williams Hematology, 6th Edition, edited by Ernest Beutler, MD, Marshall Lichtman, MD, Barry S Coller, MD, and Thomas J Kipps, MD, Ph D, Mc Graw-Hill, 2000, pp 1203-5.
15. **Kadin ME.** Hodgkin's Lymphoma, in *Comprehensive Diagnostic Immunohistochemistry*, edited by David J. Dabbs, W.B. Saunders, 2001.

16. **Kadin ME.** Ontogeny of lymphoid cells, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp.29-35, 2005.
17. **Kadin ME.** The lymphoid system, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp21-22, 2005.
18. **Kadin ME.** Structure and function of secondary lymphoid tissues and skin, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp.23-38, 2005.
19. **Kadin ME.** Histo- and Cytomorphology, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp.37-38, 2005.
20. **Kadin ME.** Classification of nodal lymphomas in historical perspective, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp79-82, 2005.
21. **Kadin ME.** Cutaneous manifestations of Hodgkin lymphoma, in *Cutaneous Lymphomas* edited by G. Burg and W. Kempf, Marcel Dekker, pp.311-312, 2005.
22. Bhargava P, **Kadin ME.** Hodgkin's Lymphoma, in *Comprehensive Diagnostic Immunohistochemistry*, edited by David J. Dabbs, W.B. Saunders, 2005.
23. **Kadin ME.** Cutaneous T-Cell and other rare T-cell non-Hodgkin lymphomas in *Pediatric Lymphomas* edited by HJ. Weinstein, MM Hudson, MP Link, Sponger-Verlag, 215-228, 2007.
24. Kempf W, Willemze R, Jaffe ES, **Kadin ME.** CD30+ T-cell lymphoproliferative disorders of the skin. in *WHO Classification of Tumours of The Skin*, IARC, pp 179-181, 2005.
25. Jaffe ES, Kerl H, **Kadin ME.** Hodgkin lymphoma. in *WHO Classification of Tumours of The Skin*, IARC, pp. 207, 2006.
26. Uguccioni M, Campbell JJ, **Kadin ME.** Lymphocyte homing and immunology of extranodal lymphoid tissues, in *Extranodal Lymphomas, Pathology and Management*, edited by H. Stein, F. Cavalli, E Zucca, Informa, Healthcare, 2008.
27. Ralfkaier E, Paulli M, Willemze R, **Kadin ME.** Primary cutaneous CD30-positive lymphoproliferative disorders; p. 300-1 in *WHO Classification of Lymphoid and Hematopoietic Tumors*, Editors Swerdlow SH, Campo E, Harris NL, IRAC, Lyon, 2008.
28. Loughran TP, Jr., **Kadin ME.** Large granular lymphocyte leukemia. In *Williams Hematology*, 7th Edition, edited by Ernest Beutler, MD, Marshall Lichtman, MD, Barry S Coller, MD, and Thomas J Kipps, MD, Ph D, Mc Graw-Hill, 2010.
29. Bhargava P, **Kadin ME.** Hodgkin Lymphoma, Chapter 5, pages 137-155, in *Diagnostic immunohistochemistry: diagnostic, theranostic, and genomic applications*, 3rd edition, edited by David J. Dabbs, MD W.B. Saunders, 2010.
30. **Kadin ME.** Cutaneous CD30+ T-cell lymphoproliferative disorders, Chapter 39, pages 604-616, in *Diagnostic Hematopathology*, Editors Elaine S. Jaffe, Nancy L. Harris, James W. Vardiman, Saunders/Elsevier, Philadelphia, 2011.
31. Cauling HD, **Kadin ME.** Patterns of lymphohistiocytic reaction in skin: an approach to cutaneous lymphohematopoietic infiltrate using histologic patterns and immunostains. pp 3-24 in *Cutaneous hematopathology- an approach to the diagnosis of atypical lymphoid-hematopoietic infiltrates in skin*. Springer NY 2014.
32. **Kadin ME,** Cuaing HD. Functional organization of the skin as an immune response organ: skin, immune response, and useful immunohistochemistry. Pp25-53 in *Cutaneous Hematopathology- An Approach to the Diagnosis of Atypical Lymphoid-Hematopoietic Infiltrates in Skin*. Springer NY 2014.
33. Cauling HD, **Kadin ME.** Role of molecular genetics and flow cytometry analysis in cutaneous hematopathology including application in ten disease categories: using molecular and immunophenotyping techniques in evaluation of hyperplasia, atypical infiltrates, and frank lymphomas. Pp.89-134 in *Cutaneous Hematopathology- An Approach*

to the Diagnosis of Atypical Lymphoid-Hematopoietic Infiltrates in Skin. Springer NY 2014.

34. **Kadin ME**, Cualing HD. Neoplastic epidermotropic diseases. Pp 135-174, 134 in Cutaneous Hematopathology- An Approach to the Diagnosis of Atypical Lymphoid-Hematopoietic Infiltrates in Skin. Springer NY 2014.
35. Willemze R, Paulli M, **Kadin ME**. Primary cutaneous CD30-positive lymphoproliferative disorders; Chapter 40 in WHO Classification of Lymphoid and Hematopoietic Tumors, editors Swerdlow SH, Campo E, Harris NL, IRAC, Lyon, 2017.
36. **Kadin ME**, Kempf W. Primary Cutaneous CD30-Positive T- cell lymphoproliferative disorders. Second edition, Chapter 40 in Hematopathology, Eds. Jaffe, ES, Harris NL, Vardiman JW, Campos E, Arber DA. Elsevier, Philadelphia, 2017.

TEXTBOOKS AND MONOGRAPHS

1. Newcom S, **Kadin ME** (editors). Diagnosis and Management of Hematologic Malignancies. Addison-Wesley, Menlo Park, 1981.
2. Hanaoka M, **Kadin ME**, Mikata A, Watanabe S. (editors) Lymphoid Malignancy. Immunocytology and Cytogenetics. Field and Wood, New York, 1990.
3. Burg G, Kempf W, Kazakov DV, **Kadin ME**, Dummer R (editors). Cutaneous Lymphomas. Taylor and Francis, Boca Raton, London, New York, Singapore. 2005.
4. Cualing HD, **Kadin ME**, Hoang MP, Morgan MB. (editors) Cutaneous Hematopathology- An Approach to the Diagnosis of Atypical Lymphoid-Hematopoietic Infiltrates in Skin. Springer New York, Heidelberg Dordrecht London, 2014, ISBN 978-1-4939-0949-0; ISBN 978-1-4939-0949-0 (eBook), Library of Congress Control Number 2014945353.

LEADERSHIP POSITIONS AT INTERNATIONAL AND NATIONAL MEETINGS

- | | |
|-----------|--|
| 9/1982 | Chairman, Seminar on Lymphoproliferative Diseases in Japan And Western Countries, Seattle, WA |
| 1984-1989 | Director, Annual Short Course On T-Cell Malignancies- United States Canadian Academy of Pathology |
| 1984-1989 | Co-Director with Cj Kjeldsberg- American Society of Clinical Pathologists- Annual Short Course on Childhood Lymphoproliferative Disorders |
| 10/1987 | Co-Chairman with Prof. Dr. Volker Diehl Workshop on The Nature of The Reed-Sternberg Cell International Symposium on Hodgkin's Lymphoma, Cologne, Germany |
| 7/1991 | Session Chairman - NATO Advanced Studies Workshop on Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation In the Skin, San Miniato, Italy |
| 10/1991 | Chairman, Workshop on Biology of The Reed-Stemberg Cell, International Symposium on Hodgkin's Disease, Cologne, Germany |
| 7/1995 | Session Chairman and Speaker, 9th Symposium on Molecular Biology of Hematopoiesis and Treatment of Leukemias And Lymphomas, Genoa, Italy. Mechanisms of Tumor Progression in CD30+ Cutaneous Lymphomas”. |
| 6/1996 | Co-Chairman, Workshop on Histological and Cytomorphological Features of Cutaneous Lymphomas, International Society of Cutaneous Lymphomas, Ascona, Switzerland |

- 12/1996 Member 3 Physician Subcommittee on Lymphocyte Biology, American Society of Hematology, San Diego, CA “Anaplastic Large-Cell Lymphoma: Pathology, Biology and Clinical Significance”
- 3/2000 Chairman and Speaker at United States Canadian Academy of Pathology Short Course on Cutaneous Lymphomas and Pseudolymphomas
- 2001 Director, Society of Hematopathology, European Association for Hematopathology, Joint Workshop on Cytogenetics and Molecular Genetics in Hematologic Malignancies, Boston, MA, Nov. 8-10, 2001
- 2001 Co-Director, Conference on State of The Art on Cutaneous Lymphomas. International Conference, Cambridge, MA, Oct 13-14, 2001
- 7/2001 Co-Director and Plenary Speaker- World Conference on Skin Cancer- Zurich, Switzerland, July 19, 2001. Two Lectures. CD30+ Cutaneous Lymphoma and Cytotoxic T Cell Lymphomas
- 6/2003 Organizer and Speaker, Histopathology Workshop and Lectures on World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Origin- Madigan General Army Hospital, Tacoma, WA
- 2000-2003 Director, Annual Short Course on Cutaneous Lymphomas and Pseudolymphomas, United States Canadian Academy of Pathology
- 7/2004 Section Chair and Plenary Session Speaker, International Symposium on Skin Cancer, Zurich Switzerland- NPM-ALK Determines the Phenotype and Consequences of CD30 Signaling in Cutaneous T-Cell Lymphomas
- 2/2005 Session Chair and Speaker, International Conference on Cutaneous Lymphomas- Berlin- NPM-ALK Abrogates Aggregation of TRAF Proteins and Activation of NF-KB in Anaplastic Large Cell Lymphoma.
- 9/2010 Co-Chair- Cutaneous 1st World Congress on Cutaneous Lymphomas, Chicago, IL CD30+ T-Cell Lymphomas
- 10/2011 UCLA/Society of Hematopathology Workshop, Marina Del Rey Ca- Session Chair and Keynote Speaker on Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders
- 10/24/14 Session Chair- New Targets for Therapy. EORTC Meeting on New Perspectives in Cutaneous Lymphomas. CD30+ Cutaneous T Cell Lymphomas are derived from A Novel Cell Type with Both Th1 And Th17 Properties.

OTHER INVITED PRESENTATIONS – INTERNATIONAL

- 9/1987 Lymphomatoid Papulosis and Ki-1+ Large Cell Lymphomas of The Skin: Pathology, Immunology, Natural History and Relevance to Hodgkin's Disease, International Colloquium on Lymphoid Malignancy, Kyoto, Japan
- 10/1987 “Ki-I Positive Large Cell Lymphoma” Scientific Lecture, NIH Pathology Panel for Lymphoma Clinical Studies, Minneapolis, MN
- 11/1987 “Cutaneous Ki- I Lymphoma - A Large Cell Lymphoma Skin Lesions” Eighteenth International Symposium of The Princess Takamatsu Cancer Research Fund, Tokyo, Japan
- 6/1988 “Clinical Correlations in Cutaneous T-Cell Lymphomas” Stanford University Current Concepts in Surgical Pathology
- 6/1988 “Childhood Lymphomas” Stanford University Current Concepts in Surgical Pathology

- 10/1988 "The Spectrum of Ki-1+ Cutaneous Lymphomas". International Symposium on Cutaneous Lymphomas, Copenhagen
- 11/1988 "Immunologic Markers in The Prognosis of Childhood Lymphomas" Children's Cancer Study Group St. Louis, MO
- 12/1988 "Diagnostic Problems in Hodgkin's Disease" American Society of Hematology San Antonio, TX
- 1/1989 "Lymphomatoid Papulosis - A Potential Model for Tumor Progression in Hodgkin's Disease and Post-Thymic T-Cell Malignancies" University of Indiana Medical Center Indianapolis, IN
- 9/1989 "Immunohistochemistry of Lymphomatoid Papulosis" Fifth International Parapsoriasis Symposium, Mayo Clinic, Rochester MN
- 10/1992 "A Cutaneous Model for T Cell Lymphomagenesis" Pathology Grand Rounds- Jefferson Medical School
- 6/1993 "Primary Ki-1-Positive Anaplastic Large-Cell Lymphoma: A Distinct Clinicopathologic Entity" Fifth International Conference on Malignant Lymphomas, Lugano, Switzerland
- 4/1994 "CD30+ Cutaneous Lymphomas" European Organization for Research and Treatment of Cancer, Cutaneous Lymphoma Project, Barcelona, Spain
- 6/1994 "Lymphomatoid Papulosis: A Model of T Cell Lymphomagenesis in The Skin". Pathology Grand Rounds- Case Western Reserve Medical School
- 6/1994 "Lymphomatoid Papulosis: A Model of T Cell Lymphomagenesis in The Skin". Pathology Grand Rounds- Case Western Reserve Medical School
- 6/1995 "Anaplastic Large Cell Lymphoma"- Memorial Sloan-Kettering Cancer Center, NY
- 9/1995 Pathology and Immunohistochemistry of Hodgkin's Disease". Canadian Association of Pathologists & Royal College of Physicians & Surgeons, Montreal, Canada
- 10/1995 "Primary Ki-1 (Cd30) Positive Cutaneous Lymphoproliferative Disorders". M.D. Anderson Hospital Conference, "Lymphoma- The Next Question," San Antonio, TX
- 3/1996 "Primary CD30+ Cutaneous Lymphomas, Including Lymphomatoid Papulosis". Clinical Implications of The Revised European American Lymphoma Classification, Cambridge MA
- 6/1996 "Cutaneous Cd30+ Lymphomas". Sixth International Conference on Malignant Lymphomas, Lugano Switzerland
- 6/1996 "Prognostic Criteria for CD30+ Lymphomas". Sixth International Conference on Malignant Lymphomas, Lugano Switzerland
- 10/1996 "Hodgkin's Disease, Histogenesis And Diagnostic Dilemmas". Society of Pediatric Oncology, Chicago, IL
- 9/1997 "Biology of CD30+ Cutaneous Lymphomas" European Society for Dermatologic Research, Berlin
- 10/1997 Lymphomas Between Hodgkin's Disease and Non- Hodgkin's Lymphomas, Wurzburg, Germany
- 3/1998 "The Border Between Hodgkin's Disease and Non-Hodgkin's Lymphoma". Society for Hematopathology, United States Canadian Academy of Pathology Meeting. Boston, MA
- 4/1998 "A Model of Cutaneous Lymphomagenesis." European Association for Haematopathology, Leiden, Netherlands

- 4/1998 “Distinction of Hodgkin's Disease and Anaplastic Large Cell Lymphoma”. Pathology Workshop Speaker, International Symposium on Hodgkin’s Disease, Cologne, Germany
- 2/1999 EORTC Workshop on Cutaneous Lymphomas of Cytotoxic Cell Origin, Florence, Italy
- 3/1999 “CD30+ Cutaneous Lymphomas: Current Knowledge and Future Directions”. American Society of Dermatopathology. San Francisco, CA
- 6/1999 EORTC Workshop on Cutaneous Pleomorphic T Cell Lymphomas, Paris, France
- 12/2000 Biology and Clinical Relevance of CD30+ Cutaneous Lymphomas, Danish Society of Dermatology, Copenhagen, Denmark
- 1/2001 Lymphomatoid Papulosis- “A Model of T Cell Lymphomagenesis in The Skin” Dermatology Grand Rounds, University of Zurich, Switzerland.
- 2/2006 Speaker, Symposium on Cutaneous Lymphomas, Zurich, Switzerland- Pathobiology of CD30+ Cutaneous T-Cell Lymphomas
- 2/2006 Charite Hospital, Berlin- Dermatology Grand Rounds- Inter-Relationship of Lymphomatoid Papulosis and Other Lymphomas
- 10/2006 Charite Hospital, Berlin- European Workshop on Cutaneous Lymphomas - Inter-Relationship of CD30+ Cutaneous Lymphomas, Atopy and Autoimmune Diseases
- 2/7/13 2nd World Congress on Cutaneous Lymphomas, Berlin, CD30 Lymphoproliferative Disorder with Pseudoepitheliomatous Hyperplasia: Possible Role of Th17 Cytokines, Neutrophils and Eosinophils
- 2/7/13 2nd World Congress on Cutaneous Lymphomas, Berlin, A Recurrent Rearrangement of 6p25.3 And Unique Pathology Identify A Previously Unrecognized Subtype of Lymphomatoid Papulosis
- 11/1/14 Th17 Cells in Lymphomas, Grand Rounds, Institute of Pathology, Frankfurt On Main, Germany
- 11/5/14 Grand Rounds, Department of Dermatology and Allergy, University of Helsinki- CD30+ Cutaneous Lymphomas- Past, Present and Future.
- 5/16/15 ALCL Update, Biomarkers to Identify Risk Factors for ALCL Basic Science, Aesthetic Surgery Education and Research Foundation, Montreal, Canada
- 10/25/16 Invited Speaker and Faculty Member, 3rd World Congress on Cutaneous Lymphomas, NY
- 01/26/17 T Cell Lymphoma Forum, San Francisco, IL-13 Is Produced by Tumor Cells in Breast Implant Associated Anaplastic Large Cell Lymphoma- Implications for Pathogenesis, Platform Presentation
- 12/05/2019 American Society of Hematology- Platform Presentation
Skin Associated *Staphylococcus Aureus* Contributes to Disease Progression in CTCL. Cosmin A Tegla, MD¹, Alberto M Herrera, MS^{2*}, Angelina M Seffens, BS^{2,3*}, Melania H Fanok, PhD^{2*}, George Dean, MD^{4*}, John Kawaoka, MD^{5*}, Mary E Laird, MD^{6*}, Yi Fulmer, PhD^{7*}, Andreas Willerslev-Olsen, PhD^{8*}, Kenneth B. Hymes, MD¹, Jo-Ann Latkowski, MD^{6*}, Niels Odum, MD, DMSci^{8*}, Stefan Feske, MD^{2*}, Bo Shopsis, MD, PhD^{7*}, Victor Torres, PhD^{9*}, Marshall E. Kadin, MD¹⁰, Larisa J Geskin, MD^{3*} and Sergei B. Koralov, PhD^{2*}

02/11/20 Mac-1/Mac-2A cells represent a potential model to study IL-13 signaling in SATB1 positive cutaneous ALCL. 4th World Congress on Cutaneous Lymphomas, Barcelona, Spain

OTHER INVITED PRESENTATIONS – NATIONAL

5/1998 “Anaplastic Large Cell Lymphoma- Past and Present Relationships to Hodgkin’s Disease and Cutaneous Lymphomas”. Pathology Grand Rounds, New York Hospital, Cornell- Medical Center

11/1998 “Biology of Anaplastic Large Cell Lymphomas and Therapeutic Implications” Children's Cancer Group Symposium on Childhood Lymphoma, Cleveland, OH

11/1999 “Anaplastic Large Cell Lymphoma: Biology, Pathology and Clinical Significance Lymphoma” Research Seminar- M.D. Anderson Cancer Center, Houston, TX

11/1999 “Newer Methods for Diagnosis of Early Cutaneous T Cell Lymphomas and Anaplastic Large Cell Lymphomas”. Quest Laboratories, San Juan Capistrano, CA

6/2000 “A Model for The Pathogenesis of Anaplastic Large Cell Lymphoma” Hematology Grand Rounds, NYU Medical Center

9/2001 Harvard CME Course on Dermatopathology-Lecture on Cutaneous T Cell Lymphomas. Sept.6, 2001

9/2001 American Association of Dermatopathology- Lecture on The Spectrum of CD30+ Cutaneous Lymphomas, Chicago, IL, Sept. 15, 2001.

10/2002 American Society of Dermatopathology, 39th Annual Meeting, Phoenix AZ

9/2004 Anaplastic Large Cell Lymphoma and Lymphomatoid Papulosis
Speaker, NIH Workshop on Environmental and Viral Causes of Lymphoma-
Role of Stem Cells and Regulatory T Cells in The Pathogenesis of
Cutaneous Lymphomas

10/2005 Speaker, Society of Hematopathology Workshop On T-Cell and NK-Cell
Malignancies How to Handle A Dominant Tumor Nodule in A Case of
Lymphomatoid Papulosis

2/2009 Cutaneous Lymphomas: Updated Classification, Pathology and Clinical
Correlation. University of Miami Dermatology Grand Rounds

10/2009 Spectrum of CD30+ Cutaneous Lymphoproliferative Disorders,
Dermatology Grand Rounds, Medical College of Wisconsin

3/2010 University of Miami Dermatology Grand Rounds, Anaplastic Large Cell
Lymphomas: A 25-Year Perspective

5/2010 Hematology-Oncology Grand Rounds, Boston University Medical Center,
Anaplastic Lymphomas: Pathology, Clinical Features and Pathogenesis

5/2011 Pathology Grand Rounds/Salhaney Memorial Lecture, University of
Pennsylvania- Lessons Learned from CD30+ Cutaneous
Lymphoproliferative Disorders

3/16/12 United States Cutaneous Lymphoma Consortium Keynote Speaker-
Cytokines in The Pathogenesis and Prognosis of Primary Cutaneous CD30+
T-Cell Lymphoproliferative Disorders

4/18/12	University of Miami Dermatology Grand Rounds, Cytokines in The Pathogenesis and Prognosis of Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders
1/28/14	T Cell Forum, San Francisco, Plasticity of T Cells in Cutaneous T Cell Lymphomas
5/16/15	Biomarkers to Identify Risk Factors for Breast Implant Associated ALCL, Clinical Implications. Premier Global Hot Topics, Aesthetic Surgery Education and Research Foundation, Montreal, Canada
3/4/15	Clonal Evolution of T Cells in Breast Implant Associated ALCL Aesthetic Surgery Education and Research Foundation, Las Vegas, NV
2/23/16	Dermatology Grand Rounds Speaker, Columbia University- Cutaneous T Cell Lymphomas
2/24/16	Research Conference, Pathology, Weill-Cornell Medical Center, Clonal Evolution of T-Cells in Breast Implant Associated T Cell Lymphomas
02/02/17	The Hematologic Malignancies and Stem Cell Transplantation Institute- City of Hope Medical Center, Los Angeles, Studies of The Pathogenesis of Breast Implant Associated ALCL
05/17/19	Preliminary Evidence of Distinguishing Cytokines Secreted by Neoplastic Cells in Breast Implant Associated Anaplastic Large Cell Lymphomas United States Canadian Academy of Pathology, Baltimore.

OTHER INVITED LECTURES – REGIONAL

6/2009	Interface Dermatitis, Pathogenesis and Clinical Significance, Dermatology Grand Rounds, Roger Williams Medical Center
8/2009	Lymphomas: Updated Classification, Pathology and Clinical Correlation, Dermatology Grand Rounds, Roger Williams Medical Center
9/15/15	Cutaneous and Breast Implant Associated ALCL, More Similarities Than Differences, Grand Rounds, Dermatology Department Roger Williams Medical Center, Providence, RI
06/30/17	Possible Origin of Anaplastic Cells from Innate Lymphoid Cells in CD30 Cutaneous Lymphoproliferative Disorders, Roger Williams Medical Center

GRANTS

Grant Study Section Reviewer

1/1994	Special reviewer for Pathology B Study Section, NIH
1994-1995	Special reviewer for Veteran's Affairs Research Merit Awards
1996	Special reviewer for General Medicine A Study Section, NIH
1998	Special reviewer for Experimental Therapeutics II, Study Section, NIH
1998	Study section for review of Laboratory of Pathology of National Cancer Institute
2003-2004	Member 2004 Specialized center of Research Program Grant Review Subcommittee of The Leukemia and Lymphoma Society
2006	NIH Subcommittee D - Clinical Studies NCID
2014-19	Italian Medicines Agency
2014	British Medical Research Council
2020	Swiss National Science Foundation

2020 Austrian Science Fund

Recent Grant Support

- 10/15/16-12/31/19 Title: Examining the role of Bacterial Superantigens in the Pathogenesis of Lymphomatoid Papulosis and Cutaneous T cell Lymphomas, 2018-19
Source: Martin and Dorothy Spatz Charitable Foundation
Award: \$175,000
Role: PI
- 01/01/18-10/31/20 Title: Pathogenesis of Breast Implant Associated Anaplastic Large Cell Lymphoma
Source: The Aesthetic Surgery Education and Research Foundation
Award: \$192,000
Role: PI
- 10/01/2019-9/30/2020 Title: Systemic Symptoms: Biospecimen Analysis Study
Source: The Aesthetic Surgery Education and Research Foundation
Pat McGuire, Washington Univ, St Louis, PI
Award: \$221,915
Subcontract to Marshall Kadin: \$70,525
Role: To assay serum cytokines and antibodies against Staphylococcal superantigens
- 01/01/2020-10/31/21 Title: Development of a diagnostic test for breast implant associated Anaplastic Large Cell Lymphoma (ALCL)
Source: Allergan, Inc.
Award: \$165,833
Role: PI
- 10/15/15-10/14/17 Title: Clonal Evolution of T Cells in Breast Implant Associated ALCL
Source: The Aesthetic Surgery Education and Research Foundation
Award: \$125,000
Role: PI
- 11/15/14-11/10/15 Title: Identification of Biomarkers in Breast Implant Associated Anaplastic Lymphoma
Source: The Aesthetic Surgery Education and Research Foundation
Award: \$99,000
Role: PI
- 1/01/12-05/30/15 Title: Preclinical in vitro study determining efficacy of efficacy of pralatrexate alone and together with other drugs used to treat peripheral T cell lymphomas.
Source: Spectrum Pharmaceutical
Award: \$80,000
Role: PI
- 6/01/08-4/30/13 Title: Center of Biomedical Research Excellence (COBRE) New Approaches to Tissue Repair.
Grant Number: NIH P20
Source: NIH/NICRR
Role: Mentor
- 3/1/11-12/31/12 Title: Pathogenesis of breast implant associated lymphomas
Source: Allergan Corporation, Irvine, CA
Award: \$68,000

Role: PI

Past Other Support

- 1/1/84-12/31/86 Principal Investigator- American Cancer Society CH254 - Cutaneous Model of Lymphomagenesis
- 1/1/88-12/31/90 Principal Investigator- Council for Tobacco Research, 2630R1 - Lymphomatoid Papulosis. A Cutaneous Model of Lymphomagenesis
- 1/1/91-12/31/92 Principal Investigator, American Cancer Society CD62577, Role of Transforming Growth Factor Beta in the Pathogenesis of Human Lymphomas
- 7/1/92-6/30/96 Principal Investigator, NIH RO1 CA54062, A Cutaneous Model of Lymphomagenesis
- 12/1/95-11/30/98 Principal Investigator/Director, Core Pathology Laboratory to detect effects of chemotherapy on cell proliferation, angiogenesis and tumor antigens in NIH PO1CA 38493-10A2 to Dana-Farber Cancer Center Solid Tumor Autologous Marrow Transplant Program. Principal Investigator of Program Project, Emil Frei III, MD
- 12/31/97-12/31/00 Principal Investigator, Leukemia Society of America (178-98) Abnormal receptor for Transforming Growth Factor-Beta in Chronic Lymphocytic Leukemia
- 7/1/97-12/31/98 Principal Investigator, Berlex Laboratories. Defective receptors for TGF- β in Chronic Lymphocytic Leukemia
- 11/1/97- 3/31/ 98 Principal Investigator, American Cancer Society ROG-98-125-01 Model of Lymphomagenesis
- 11/1/99-11/30/00 Sponsor, Grant from the Swiss National Science Foundation to Werner Kempf, MD, PhD, for study of T cell Lymphotropic Virus in Lymphomatoid Papulosis
- 9/1/98-3/30/99 Sponsor, Grant from Biomedical Sciences Exchange Program between North America and Europe to Sabine Seth, MD, for study of Prognostic Markers in Hodgkin's Disease
- 5/1/97-4/30/99 Sponsor, Grant from German Cancer Foundation, Mildred Scheel Stiftung fur Krebsforschung to Walther Pfeifer, MD, Role of Transforming Growth Factor Beta in Lymphoma Progression, May 1997-April 1999
- 7/1/98-6/30/99 Sponsor, Grant from Lymphoma Research Foundation of America to Edi Levi, MD, PhD, CD30 ligand in Hodgkin's Disease and Non-Hodgkin's Lymphoma
- 7/1/98-6/30/99 Sponsor, Grant from Cure for Lymphoma Foundation to Tina Haliotis, MD, PhD, The role of cellular immunity in the regression of CD30+ cutaneous lymphomas
- 1/1/98-12/31/98 Sponsor, Grant from Phillipe Foundation, France to Olivier Dereure, MD, for study of Mechanisms of Apoptosis and Tumor Cell Survival in Cutaneous T Cell Lymphoma
- 7/1/04-11/30/04 Sponsor, American Society of Hematology Young Investigator Award to Samuel Howell for research on fetal microchimerism in cutaneous T-cell lymphomas

Past Other Support (Continued)

- 10/01/01-9/30/06 Title: Spore in Skin Cancer
Grant Number: PO-CA93683
Thomas Kupper, MD, PI
Source: NIH/NCI
Role: Co-investigator
- 5/30/07-4/30/08 Title: The New Stem Cell Biology (COBRE)
Grant Number: 1P20 RR018757-01
Source: NIH, NCRR
Role: Mentor

UNIVERSITY TEACHING, ADVISING, and MENTORING ROLES

University of Washington, Seattle

- 1977-1984 Lecturer, Laboratory Medicine 425, Clinical Hematology, 20 students, preparation 10 hours, contact time 3 hours
- 1977-1984 Lecturer, Laboratory Medicine 501, Clinical Laboratory Diagnosis, 10 students and technicians, 10 hours preparation, 4 hours contact time
- 1980-1984 Course Director and Lecturer, Laboratory Medicine Course 521, Advanced Laboratory Hematology, planned course for 12 residents and 6 students, 20 hours preparation, contact time 12 hours
- 1980-1984 Course organizing committee and lecturer, Human Biology 561, 120 students, Hematology, 12 hours preparation, contact time 4 hours
- 1980-1984 Lecturer, Pathology 574, Systemic Pathology, 120 students, 12 hours preparation, 1-hour contact time
- 1980-1984 Lecturer, Pathology 444B, General Pathology, 120 students, 8 hours preparation, 1-hour contact time

Harvard Medical School

- 1994-1996 Tutor and Section Leader, Human Systems Hematology Course 708.0, second year medical students; 6-8 students/ tutorial, 12 hours preparation, 16/20 students/section, preparation over 3 weeks, 25 hours contact time
- 1994-1999 Pathology Section Leader, 40 students, 2 hours preparation, 3 hours contact time
- 1998 Section Leader in Immunology, Microbiology and Infectious disease; 20 students, 10 hours preparation, 12 hours contact time

HOSPITAL TEACHING, ADVISING, and MENTORING ROLES

BIDMC Lymphoma Conference

- 1998- 2002 I organized and taught in a monthly lymphoma conference for the faculty and fellows in hematology-oncology, and pathology residents at Beth Israel Deaconess Medical Center. Clinical management, histopathogenesis, diagnosis, immunopathology and molecular biology of lymphomas are presented and discussed. 30 hours preparation, 15 contact hours

Clinical Pathology Lecture Series

1996-2002 14 lectures on structure and function of the immune system, reactive lymphadenopathies, low- and high-grade B cell lymphomas, plasma cell dyscrasias, Hodgkin's disease, childhood lymphomas, extranodal lymphomas, HIV associated lymphadenopathy, T cell lymphomas, chronic lymphocytic leukemias, myelodysplastic disorders, acute myelogenous leukemia, chronic myelogenous leukemia and other myeloproliferative disorders. 12-16 residents and fellows, 28 hours preparation, 14 hours contact time

Dermatopathology Lecture Series

1994-2002 One or two lectures each year on cutaneous T cell lymphomas and cutaneous B cell lymphomas, 12-14 residents/fellows, preparation 4 hours, 2 hours contact time

Hematology/Oncology Orientation Lectures

1984-2004 One or two lectures each year on Immunologic markers and diagnosis of leukemias and lymphomas, 20-25 residents/fellows and students, 4 hours preparation, 2 hours contact time

Morbidity and Mortality Conference

1984-2002 3-4 hourly conferences per year. Discussion of pathology and clinical implications in management of hematologic disorders. Department of Medicine house staff and faculty, 2 hours preparation, 2 hours contact time

Department of Medicine Firm Conference

1984-2002 Six to eight 90-minute conferences per year, discussion of pathology and clinical implications, Department of Medicine house staff and faculty from medicine and radiology, 1 hours preoperation, 1 hours contact time

Clinical Pathology Elective

1994-1998 Bone marrow, peripheral blood and lymph node morphology teaching at microscope with one to two medical students several times per year, 1 hour preparation, 3 hours contact time per student

Surgical Pathology Conference

1984-2002 Discussion of clinical teaching cases with 12-15 residents/fellows and faculty, 10 hours preoperation, 10-12 hours contact time per year

Autopsy Conference

1984-1990 Discussion of pathologic findings at autopsy table with 8-16 pathology and medical residents and students, 10 hours preparation, 10-12 hours contact time per year

Graduate Medical Courses

1984-2002 Weekly Hematology/Oncology Teaching Rounds, fellows, residents and students, 10 hours preparation, 40 hours contact time

2007-present Roger Williams Medical Center, affiliated with Boston University, 5 dermatology grand rounds, weekly teaching conferences in dermatology including correlation of patient clinical features and dermatopathology,

consult on difficult cases for dermatopathologists at Roger Williams, 10 hours preoperation, 40 hours contact time

See patients with residents in the Cutaneous Lymphoma Clinic established at RWMC, most patients come from out-of-state seeking a second opinion on their disease, 20 hours preparation, 60 hours contact time

Current Mentoring Steven C. Katz, MD, FACS, Director of Surgical Oncology Fellowship, Director of Surgical Immunotherapy, Associate Professor of Surgery, Roger Williams Medical Center
Immunotherapy of disseminated cancers

Dean George, MD- Senior Resident in Dermatology
Skin associated Staphylococcus aureus contributes to disease progression in cutaneous T cell lymphoma.

Mithun Sinha, PhD
Assistant Professor of Surgery
University of Indiana
Role of Biofilm Derived Oxylipin Immune Response in Development of Breast Implant Illness

Victoria Zeyl- Fourth year medical student, Brown Alpert School of Medicine
Development of Point of Care Testing for Breast Implant Associated ALCL

Kelly Fan, Undergraduate student, Brown University- Investigating the role of IL-9 in the pathogenesis of BIA-ALCL